ALS (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "ALS" in English language version.

refsWebsite

Global rank English rank

179nih.gov

4^th place

122doi.org

2^nd place

47semanticscholar.org

11^th place

8^th place

27web.archive.org

1^st place

7handle.net

102^nd place

76^th place

5worldcat.org

5^th place

4als.org

low place

4harvard.edu

18^th place

17^th place

2whiterose.ac.uk

4,124^th place

2,320^th place

2oup.com

485^th place

440^th place

2kcl.ac.uk

3,833^rd place

2,331^st place

2fda.gov

447^th place

338^th place

1medlineplus.gov

1,581^st place

1,299^th place

1who.int

195^th place

302^nd place

1archive.today

14^th place

1kuleuven.be

4,725^th place

3,556^th place

1bmj.com

1,226^th place

1,421^st place

1nhs.uk

1,989^th place

1,528^th place

1arxiv.org

69^th place

59^th place

1uni-muenchen.de

3,337^th place

3,444^th place

1archives-ouvertes.fr

1,031^st place

879^th place

1cnn.com

28^th place

26^th place

1mayoclinic.org

1,610^th place

1,279^th place

1qut.edu.au

8,570^th place

5,097^th place

1elsevier.com

610^th place

704^th place

1annualreviews.org

3,867^th place

3,957^th place

1knowablemagazine.org

low place

6,670^th place

1medscape.com

719^th place

636^th place

1lems.com

low place

1asha.org

low place

9,614^th place

1apnews.com

129^th place

89^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

1medpagetoday.com

9,274^th place

5,856^th place

1alsa.org

low place

1mda.org

low place

1independent.co.uk

36^th place

33^rd place

als.org

"Understanding ALS". The ALS Association. Archived from the original on 26 October 2020. Retrieved 28 October 2020.
"FDA-Approved Drugs for Treating ALS". The ALS Association. Archived from the original on 25 April 2023. Retrieved 25 April 2023.
"Who Gets ALS?". The ALS Association. Archived from the original on 6 April 2022. Retrieved 6 April 2022.
"AMX0035 (RELYVRIO)". The ALS Association. Archived from the original on 25 April 2023. Retrieved 25 April 2023.

alsa.org

"What is ALS?". The ALS Association. Archived from the original on 21 December 2018. Retrieved 23 December 2018.

annualreviews.org

Frost B, Dubnau J (8 August 2024). "The Role of Retrotransposons and Endogenous Retroviruses in Age-Dependent Neurodegenerative Disorders". Annual Review of Neuroscience. 47 (1): 123–143. doi:10.1146/annurev-neuro-082823-020615. ISSN 0147-006X.

apnews.com

"ALS drug will be pulled from US market after study showed patients didn't benefit". AP News. 4 April 2024. Retrieved 4 April 2024.

archive.today

"8B60 Motor neuron disease". ICD-11 for Mortality and Morbidity Statistics. World Health Organization. Archived from the original on 1 August 2018. Retrieved 24 January 2019.

archives-ouvertes.fr

hal.archives-ouvertes.fr

Chiò A, Calvo A, Moglia C, Mazzini L, Mora G (July 2011). "Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study" (PDF). Journal of Neurology, Neurosurgery, and Psychiatry. 82 (7): 740–746. doi:10.1136/jnnp.2010.235952. PMID 21402743. S2CID 13416164. Archived (PDF) from the original on 24 November 2022. Retrieved 4 August 2022.

arxiv.org

Chiò A, Mora G, Lauria G (February 2017). "Pain in amyotrophic lateral sclerosis". The Lancet. Neurology. 16 (2): 144–157. arXiv:1607.02870. doi:10.1016/S1474-4422(16)30358-1. PMID 27964824. S2CID 38905437.

asha.org

"Amyotrophic Lateral Sclerosis (ALS)". American Speech-Language-Hearing Association, Rockville, MD. Archived from the original on 2 August 2012. Retrieved 30 November 2016.

bmj.com

jnnp.bmj.com

Mehta PR, Jones AR, Opie-Martin S, Shatunov A, Iacoangeli A, Khleifat AA, et al. (1 March 2019). "Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias". Journal of Neurology, Neurosurgery & Psychiatry. 90 (3): 268–271. doi:10.1136/jnnp-2018-319089. ISSN 0022-3050. PMC 6518463. PMID 30270202.

clinicaltrials.gov

Amylyx Pharmaceuticals Inc. (4 January 2023). A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (ALS) (Report). clinicaltrials.gov.

cnn.com

Landau E (20 September 2009). "Stephen Hawking serves as role model for ALS patients". CNN. Archived from the original on 15 August 2016.

doi.org

Wijesekera LC, Leigh PN (February 2009). "Amyotrophic lateral sclerosis". Orphanet Journal of Rare Diseases. 4 (4): 3. doi:10.1186/1750-1172-4-3. PMC 2656493. PMID 19192301.
Masrori P, Van Damme P (October 2020). "Amyotrophic lateral sclerosis: a clinical review". European Journal of Neurology. 27 (10): 1918–1929. doi:10.1111/ene.14393. PMC 7540334. PMID 32526057.
Kwan J, Vullaganti M (September 2022). "Amyotrophic lateral sclerosis mimics". Muscle & Nerve. 66 (3): 240–252. doi:10.1002/mus.27567. PMID 35607838. S2CID 249014375.
Hobson EV, McDermott CJ (September 2016). "Supportive and symptomatic management of amyotrophic lateral sclerosis" (PDF). Nature Reviews. Neurology. 12 (9): 526–538. doi:10.1038/nrneurol.2016.111. PMID 27514291. S2CID 8547381. Archived (PDF) from the original on 1 December 2020. Retrieved 20 December 2019.
Goutman SA, Hardiman O, Al-Chalabi A, Chió A, Savelieff MG, Kiernan MC, et al. (May 2022). "Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis". The Lancet. Neurology. 21 (5): 480–493. doi:10.1016/S1474-4422(21)00465-8. PMC 9513753. PMID 35334233.
Ryan M, Heverin M, McLaughlin RL, Hardiman O (November 2019). "Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis". JAMA Neurology. 76 (11): 1367–1374. doi:10.1001/jamaneurol.2019.2044. PMC 6646974. PMID 31329211.
van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. (November 2017). "Amyotrophic lateral sclerosis". Lancet. 390 (10107): 2084–2098. doi:10.1016/S0140-6736(17)31287-4. hdl:2318/1673185. PMID 28552366. S2CID 24483077.
Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. (October 2017). "Amyotrophic lateral sclerosis" (PDF). Nature Reviews. Disease Primers. 3 (17071): 17071. doi:10.1038/nrdp.2017.71. PMID 28980624. S2CID 1002680. Archived (PDF) from the original on 1 December 2020. Retrieved 20 December 2019.
Wingo TS, Cutler DJ, Yarab N, Kelly CM, Glass JD (2011). "The heritability of amyotrophic lateral sclerosis in a clinically ascertained United States research registry". PLOS ONE. 6 (11): e27985. Bibcode:2011PLoSO...627985W. doi:10.1371/journal.pone.0027985. PMC 3222666. PMID 22132186.
Goutman SA, Hardiman O, Al-Chalabi A, Chió A, Savelieff MG, Kiernan MC, et al. (May 2022). "Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis". The Lancet. Neurology. 21 (5): 465–479. doi:10.1016/S1474-4422(21)00414-2. PMC 9513754. PMID 35334234.
Soriani MH, Desnuelle C (May 2017). "Care management in amyotrophic lateral sclerosis". Revue Neurologique. 173 (5): 288–299. doi:10.1016/j.neurol.2017.03.031. PMID 28461024.
Connolly S, Galvin M, Hardiman O (April 2015). "End-of-life management in patients with amyotrophic lateral sclerosis". The Lancet. Neurology. 14 (4): 435–442. doi:10.1016/S1474-4422(14)70221-2. PMID 25728958. S2CID 34109901.
Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. (March 2011). "Amyotrophic lateral sclerosis". Lancet. 377 (9769): 942–955. doi:10.1016/s0140-6736(10)61156-7. PMID 21296405.
Pupillo E, Messina P, Logroscino G, Beghi E (February 2014). "Long-term survival in amyotrophic lateral sclerosis: a population-based study". Annals of Neurology. 75 (2): 287–297. doi:10.1002/ana.24096. PMID 24382602. S2CID 205345019.
Rowland LP (March 2001). "How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot". Archives of Neurology. 58 (3): 512–515. doi:10.1001/archneur.58.3.512. PMID 11255459.
van Eenennaam RM, Koppenol LS, Kruithof WJ, Kruitwagen-van Reenen ET, Pieters S, van Es MA, et al. (November 2021). "Discussing Personalized Prognosis Empowers Patients with Amyotrophic Lateral Sclerosis to Regain Control over Their Future: A Qualitative Study". Brain Sciences. 11 (12): 1597. doi:10.3390/brainsci11121597. PMC 8699408. PMID 34942899.
Grad LI, Rouleau GA, Ravits J, Cashman NR (August 2017). "Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS)". Cold Spring Harbor Perspectives in Medicine. 7 (8): a024117. doi:10.1101/cshperspect.a024117. PMC 5538408. PMID 28003278.
Gautier G, Verschueren A, Monnier A, Attarian S, Salort-Campana E, Pouget J (August 2010). "ALS with respiratory onset: clinical features and effects of non-invasive ventilation on the prognosis". Amyotrophic Lateral Sclerosis. 11 (4): 379–382. doi:10.3109/17482960903426543. PMID 20001486. S2CID 27672209.
Swinnen B, Robberecht W (November 2014). "The phenotypic variability of amyotrophic lateral sclerosis". Nature Reviews. Neurology. 10 (11): 661–670. doi:10.1038/nrneurol.2014.184. PMID 25311585. S2CID 205516010. Archived from the original on 31 December 2018. Retrieved 22 August 2018.
Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH (October 2016). "Amyotrophic lateral sclerosis: moving towards a new classification system". The Lancet. Neurology. 15 (11): 1182–1194. doi:10.1016/S1474-4422(16)30199-5. hdl:2318/1636249. PMID 27647646. S2CID 45285510.
Jawdat O, Statland JM, Barohn RJ, Katz JS, Dimachkie MM (November 2015). "Amyotrophic Lateral Sclerosis Regional Variants (Brachial Amyotrophic Diplegia, Leg Amyotrophic Diplegia, and Isolated Bulbar Amyotrophic Lateral Sclerosis)". Neurologic Clinics. 33 (4): 775–785. doi:10.1016/j.ncl.2015.07.003. PMC 4629514. PMID 26515621.
Zhang H, Chen L, Tian J, Fan D (October 2021). "Disease duration of progression is helpful in identifying isolated bulbar palsy of amyotrophic lateral sclerosis". BMC Neurology. 21 (1): 405. doi:10.1186/s12883-021-02438-8. PMC 8532334. PMID 34686150.
Mehta PR, Jones AR, Opie-Martin S, Shatunov A, Iacoangeli A, Khleifat AA, et al. (1 March 2019). "Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias". Journal of Neurology, Neurosurgery & Psychiatry. 90 (3): 268–271. doi:10.1136/jnnp-2018-319089. ISSN 0022-3050. PMC 6518463. PMID 30270202.
Lehky T, Grunseich C (November 2021). "Juvenile Amyotrophic Lateral Sclerosis: A Review". Genes. 12 (12): 1935. doi:10.3390/genes12121935. PMC 8701111. PMID 34946884.
Teoh HL, Carey K, Sampaio H, Mowat D, Roscioli T, Farrar M (2017). "Inherited Paediatric Motor Neuron Disorders: Beyond Spinal Muscular Atrophy". Neural Plasticity. 2017: 6509493. doi:10.1155/2017/6509493. PMC 5467325. PMID 28634552.
Tard C, Defebvre L, Moreau C, Devos D, Danel-Brunaud V (May 2017). "Clinical features of amyotrophic lateral sclerosis and their prognostic value". Revue Neurologique. 173 (5): 263–272. doi:10.1016/j.neurol.2017.03.029. PMID 28477850.
Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L, et al. (May 2013). "Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 14 (Suppl 1): 5–18. doi:10.3109/21678421.2013.778548. PMC 3779649. PMID 23678876.
Chiò A, Mora G, Lauria G (February 2017). "Pain in amyotrophic lateral sclerosis". The Lancet. Neurology. 16 (2): 144–157. arXiv:1607.02870. doi:10.1016/S1474-4422(16)30358-1. PMID 27964824. S2CID 38905437.
Gromicho M, Figueiral M, Uysal H, Grosskreutz J, Kuzma-Kozakiewicz M, Pinto S, et al. (July 2020). "Spreading in ALS: The relative impact of upper and lower motor neuron involvement". Annals of Clinical and Translational Neurology. 7 (7): 1181–1192. doi:10.1002/acn3.51098. PMC 7359118. PMID 32558369.
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. (October 1999). "The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)". Journal of the Neurological Sciences. 169 (1–2): 13–21. doi:10.1016/s0022-510x(99)00210-5. PMID 10540002. S2CID 7057926.
Wong C, Stavrou M, Elliott E, Gregory JM, Leigh N, Pinto AA, et al. (2021). "Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective". Brain Communications. 3 (4): fcab242. doi:10.1093/braincomms/fcab242. PMC 8659356. PMID 34901853.
Creemers H, Grupstra H, Nollet F, van den Berg LH, Beelen A (June 2015). "Prognostic factors for the course of functional status of patients with ALS: a systematic review". Journal of Neurology. 262 (6): 1407–1423. doi:10.1007/s00415-014-7564-8. PMID 25385051. S2CID 31734765.
Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. (November 2014). "The PRO-ACT database: design, initial analyses, and predictive features". Neurology. 83 (19): 1719–1725. doi:10.1212/WNL.0000000000000951. PMC 4239834. PMID 25298304.
Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, et al. (March 2016). "How common are ALS plateaus and reversals?". Neurology. 86 (9): 808–812. doi:10.1212/WNL.0000000000002251. PMC 4793781. PMID 26658909.
Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME (2010). "Clinical significance in the change of decline in ALSFRS-R". Amyotrophic Lateral Sclerosis (Journal Article). 11 (1–2): 178–180. doi:10.3109/17482960903093710. PMID 19634063. S2CID 207619689.
Yunusova Y, Plowman EK, Green JR, Barnett C, Bede P (2019). "Clinical Measures of Bulbar Dysfunction in ALS". Frontiers in Neurology. 10: 106. doi:10.3389/fneur.2019.00106. PMC 6389633. PMID 30837936.
Lui AJ, Byl NN (June 2009). "A systematic review of the effect of moderate intensity exercise on function and disease progression in amyotrophic lateral sclerosis". Journal of Neurologic Physical Therapy. 33 (2): 68–87. doi:10.1097/NPT.0b013e31819912d0. PMID 19556916. S2CID 7650356.
Beukelman D, Fager S, Nordness A (2011). "Communication Support for People with ALS". Neurology Research International. 2011: 714693. doi:10.1155/2011/714693. PMC 3096454. PMID 21603029.
Kuzma-Kozakiewicz M, Andersen PM, Ciecwierska K, Vázquez C, Helczyk O, Loose M, et al. (September 2019). "An observational study on quality of life and preferences to sustain life in locked-in state". Neurology. 93 (10): e938 – e945. doi:10.1212/WNL.0000000000008064. PMC 6745736. PMID 31391247.
O'Brien D, Stavroulakis T, Baxter S, Norman P, Bianchi S, Elliott M, et al. (September 2019). "The optimisation of noninvasive ventilation in amyotrophic lateral sclerosis: a systematic review". The European Respiratory Journal. 54 (3): 1900261. doi:10.1183/13993003.00261-2019. PMID 31273038. S2CID 195805546.
Bede P, Oliver D, Stodart J, van den Berg L, Simmons Z, O Brannagáin D, et al. (April 2011). "Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives". Journal of Neurology, Neurosurgery, and Psychiatry. 82 (4): 413–418. doi:10.1136/jnnp.2010.232637. hdl:2262/59035. PMID 21297150. S2CID 7043837. Archived from the original on 28 May 2023. Retrieved 30 April 2023.
Corcia P, Pradat PF, Salachas F, Bruneteau G, Forestier N, Seilhean D, et al. (1 January 2008). "Causes of death in a post-mortem series of ALS patients". Amyotrophic Lateral Sclerosis. 9 (1): 59–62. doi:10.1080/17482960701656940. PMID 17924236. S2CID 40367873.
Fang T, Al Khleifat A, Stahl DR, Lazo La Torre C, Murphy C, Young C, et al. (May 2017). "Comparison of the King's and MiToS staging systems for ALS". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 18 (3–4): 227–232. doi:10.1080/21678421.2016.1265565. PMC 5425622. PMID 28054828.
Chiò A, Calvo A, Moglia C, Mazzini L, Mora G (July 2011). "Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study" (PDF). Journal of Neurology, Neurosurgery, and Psychiatry. 82 (7): 740–746. doi:10.1136/jnnp.2010.235952. PMID 21402743. S2CID 13416164. Archived (PDF) from the original on 24 November 2022. Retrieved 4 August 2022.
Martin S, Al Khleifat A, Al-Chalabi A (2017). "What causes amyotrophic lateral sclerosis?". F1000Research. 6: 371. doi:10.12688/f1000research.10476.1. PMC 5373425. PMID 28408982.
Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, et al. (October 2018). "ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS". Neurology. 91 (15): e1370 – e1380. doi:10.1212/WNL.0000000000006317. PMC 6177274. PMID 30209236.
Yang T, Hou Y, Li C, Cao B, Cheng Y, Wei Q, et al. (July 2021). "Risk factors for cognitive impairment in amyotrophic lateral sclerosis: a systematic review and meta-analysis". Journal of Neurology, Neurosurgery, and Psychiatry. 92 (7): 688–693. doi:10.1136/jnnp-2020-325701. PMID 33563800. S2CID 231858696.
Wicks P (July 2007). "Excessive yawning is common in the bulbar-onset form of ALS". Acta Psychiatrica Scandinavica. 116 (1): 76, author reply 76–76, author reply 77. doi:10.1111/j.1600-0447.2007.01025.x. PMID 17559605. S2CID 12807996.
Sauvé WM (December 2016). "Recognizing and treating pseudobulbar affect". CNS Spectrums. 21 (S1): 34–44. doi:10.1017/S1092852916000791. PMID 28044945. S2CID 21066800.
Raaphorst J, Beeldman E, De Visser M, De Haan RJ, Schmand B (October 2012). "A systematic review of behavioural changes in motor neuron disease". Amyotrophic Lateral Sclerosis. 13 (6): 493–501. doi:10.3109/17482968.2012.656652. PMID 22424127. S2CID 22224140.
Couratier P, Corcia P, Lautrette G, Nicol M, Marin B (May 2017). "ALS and frontotemporal dementia belong to a common disease spectrum". Revue Neurologique. 173 (5): 273–279. doi:10.1016/j.neurol.2017.04.001. PMID 28449882.
Renton AE, Chiò A, Traynor BJ (January 2014). "State of play in amyotrophic lateral sclerosis genetics". Nature Neuroscience. 17 (1): 17–23. doi:10.1038/nn.3584. hdl:2318/156177. PMC 4544832. PMID 24369373.
Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, de Haan RJ (June 2016). "The cognitive profile of ALS: a systematic review and meta-analysis update". Journal of Neurology, Neurosurgery, and Psychiatry. 87 (6): 611–619. doi:10.1136/jnnp-2015-310734. PMID 26283685. S2CID 22082109.
Al-Chalabi A, Hardiman O (November 2013). "The epidemiology of ALS: a conspiracy of genes, environment and time". Nature Reviews. Neurology. 9 (11): 617–628. doi:10.1038/nrneurol.2013.203. PMID 24126629. S2CID 25040863.
He J, Mangelsdorf M, Fan D, Bartlett P, Brown MA (December 2015). "Amyotrophic Lateral Sclerosis Genetic Studies: From Genome-wide Association Mapping to Genome Sequencing" (PDF). The Neuroscientist. 21 (6): 599–615. doi:10.1177/1073858414555404. PMID 25378359. S2CID 3437565. Archived (PDF) from the original on 7 May 2020. Retrieved 20 December 2019.
McNeill A, Amador MD, Bekker H, Clarke A, Crook A, Cummings C, et al. (June 2022). "Predictive genetic testing for Motor neuron disease: time for a guideline?". European Journal of Human Genetics. 30 (6): 635–636. doi:10.1038/s41431-022-01093-y. PMC 9177585. PMID 35379930.
De Oliveira HM, Soma A, Baker MR, Turner MR, Talbot K, Williams TL (August 2023). "A survey of current practice in genetic testing in amyotrophic lateral sclerosis in the UK and Republic of Ireland: implications for future planning". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 24 (5–6): 405–413. doi:10.1080/21678421.2022.2150556. PMID 36458618. S2CID 254150195.
Müller K, Oh KW, Nordin A, Panthi S, Kim SH, Nordin F, et al. (February 2022). "De novo mutations in SOD1 are a cause of ALS". Journal of Neurology, Neurosurgery, and Psychiatry. 93 (2): 201–206. doi:10.1136/jnnp-2021-327520. PMC 8784989. PMID 34518333.
Mehta PR, Iacoangeli A, Opie-Martin S, van Vugt JJ, Al Khleifat A, Bredin A, et al. (19 December 2022). "The impact of age on genetic testing decisions in amyotrophic lateral sclerosis". Brain. 145 (12): 4440–4447. doi:10.1093/brain/awac279. ISSN 0006-8950. PMC 9762932. PMID 36162820.
Salmon K, Kiernan MC, Kim SH, Andersen PM, Chio A, van den Berg LH, et al. (May 2022). "The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis". Brain. 145 (4): 1207–1210. doi:10.1093/brain/awab472. PMC 9129091. PMID 35020823. Archived from the original on 27 May 2023. Retrieved 27 May 2023.
Wang MD, Little J, Gomes J, Cashman NR, Krewski D (July 2017). "Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis". Neurotoxicology. 61: 101–130. Bibcode:2017NeuTx..61..101W. doi:10.1016/j.neuro.2016.06.015. PMID 27377857. S2CID 33604904. Archived from the original on 17 November 2022. Retrieved 27 May 2023.
Vitturi BK, Montecucco A, Rahmani A, Dini G, Durando P (15 November 2023). "Occupational risk factors for multiple sclerosis: a systematic review with meta-analysis". Frontiers in Public Health. 11 (2023): Introduction. Bibcode:2023FrPH...1185103V. doi:10.3389/fpubh.2023.1285103. PMC 10694508. PMID 38054069.
Grossman AB, Levin BE, Bradley WG (March 2006). "Premorbid personality characteristics of patients with ALS". Amyotrophic Lateral Sclerosis. 7 (1): 27–31. doi:10.1080/14660820510012004. PMID 16546756. S2CID 20998807.
Parkin Kullmann JA, Hayes S, Pamphlett R (October 2018). "Are people with amyotrophic lateral sclerosis (ALS) particularly nice? An international online case-control study of the Big Five personality factors". Brain and Behavior. 8 (10): e01119. doi:10.1002/brb3.1119. PMC 6192405. PMID 30239176.
Mehl T, Jordan B, Zierz S (January 2017). ""Patients with amyotrophic lateral sclerosis (ALS) are usually nice persons"-How physicians experienced in ALS see the personality characteristics of their patients". Brain and Behavior. 7 (1): e00599. doi:10.1002/brb3.599. PMC 5256182. PMID 28127517.
Frost B, Dubnau J (8 August 2024). "The Role of Retrotransposons and Endogenous Retroviruses in Age-Dependent Neurodegenerative Disorders". Annual Review of Neuroscience. 47 (1): 123–143. doi:10.1146/annurev-neuro-082823-020615. ISSN 0147-006X.
Dance A (17 June 2025). "How rogue jumping genes can spur Alzheimer's, ALS". doi:10.1146/knowable-061725-1. {{cite journal}}: Cite journal requires |journal= (help)
Robberecht W, Philips T (April 2013). "The changing scene of amyotrophic lateral sclerosis". Nature Reviews. Neuroscience. 14 (4): 248–264. doi:10.1038/nrn3430. PMID 23463272. S2CID 208941.
Brown RH, Al-Chalabi A (July 2017). "Amyotrophic Lateral Sclerosis". The New England Journal of Medicine. 377 (2): 162–172. doi:10.1056/NEJMra1603471. PMID 28700839. S2CID 205117619. Archived from the original on 25 February 2021. Retrieved 20 December 2019.
Okamoto K, Mizuno Y, Fujita Y (April 2008). "Bunina bodies in amyotrophic lateral sclerosis". Neuropathology. 28 (2): 109–115. doi:10.1111/j.1440-1789.2007.00873.x. PMID 18069968. S2CID 34398467.
White JA, Banerjee R, Gunawardena S (May 2016). "Axonal Transport and Neurodegeneration: How Marine Drugs Can Be Used for the Development of Therapeutics". Marine Drugs. 14 (5): 102. doi:10.3390/md14050102. PMC 4882576. PMID 27213408.
Ng Kee Kwong KC, Mehta AR, Nedergaard M, Chandran S (August 2020). "Defining novel functions for cerebrospinal fluid in ALS pathophysiology". Acta Neuropathologica Communications. 8 (1): 140. doi:10.1186/s40478-020-01018-0. PMC 7439665. PMID 32819425.
Van Damme P, Robberecht W, Van Den Bosch L (May 2017). "Modelling amyotrophic lateral sclerosis: progress and possibilities". Disease Models & Mechanisms. 10 (5): 537–549. doi:10.1242/dmm.029058. PMC 5451175. PMID 28468939.
Alsultan AA, Waller R, Heath PR, Kirby J (2016). "The genetics of amyotrophic lateral sclerosis: current insights". Degenerative Neurological and Neuromuscular Disease. 6: 49–64. doi:10.2147/DNND.S84956. PMC 6053097. PMID 30050368.
Shang Y, Huang EJ (September 2016). "Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis". Brain Research. 1647: 65–78. doi:10.1016/j.brainres.2016.03.036. PMC 5003642. PMID 27033831.
Mehta PR, Brown AL, Ward ME, Fratta P (15 March 2023). "The era of cryptic exons: implications for ALS-FTD". Molecular Neurodegeneration. 18 (1): 16. doi:10.1186/s13024-023-00608-5. ISSN 1750-1326. PMC 10018954. PMID 36922834.
Nguyen HP, Van Broeckhoven C, van der Zee J (June 2018). "ALS Genes in the Genomic Era and their Implications for FTD". Trends in Genetics. 34 (6): 404–423. doi:10.1016/j.tig.2018.03.001. hdl:10067/1514730151162165141. PMID 29605155.
Gitler AD, Tsuiji H (September 2016). "There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS". Brain Research. 1647: 19–29. doi:10.1016/j.brainres.2016.04.004. PMC 5003651. PMID 27059391.
Mehta AR, Gregory JM, Dando O, Carter RN, Burr K, Nanda J, et al. (February 2021). "Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis". Acta Neuropathologica. 141 (2): 257–279. doi:10.1007/s00401-020-02252-5. PMC 7847443. PMID 33398403.
Verber NS, Shepheard SR, Sassani M, McDonough HE, Moore SA, Alix JJ, et al. (2019). "Biomarkers in Motor Neuron Disease: A State of the Art Review". Frontiers in Neurology. 10: 291. doi:10.3389/fneur.2019.00291. PMC 6456669. PMID 31001186.
Joyce NC, Carter GT (May 2013). "Electrodiagnosis in persons with amyotrophic lateral sclerosis". PM&R. 5 (5 Suppl): S89 – S95. doi:10.1016/j.pmrj.2013.03.020. PMC 4590769. PMID 23523708.
Silani V, Messina S, Poletti B, Morelli C, Doretti A, Ticozzi N, et al. (March 2011). "The diagnosis of Amyotrophic lateral sclerosis in 2010". Archives Italiennes de Biologie. 149 (1): 5–27. doi:10.4449/aib.v149i1.1260 (inactive 22 January 2025). PMID 21412713.{{cite journal}}: CS1 maint: DOI inactive as of January 2025 (link)
Mills KR (November 2010). "Characteristics of fasciculations in amyotrophic lateral sclerosis and the benign fasciculation syndrome". Brain. 133 (11): 3458–3469. doi:10.1093/brain/awq290. PMID 20959307.
Radunovic A, Annane D, Rafiq MK, Brassington R, Mustfa N (October 2017). "Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease". The Cochrane Database of Systematic Reviews. 10 (10): CD004427. doi:10.1002/14651858.CD004427.pub4. PMC 6485636. PMID 28982219.
Ahmed RM, Newcombe RE, Piper AJ, Lewis SJ, Yee BJ, Kiernan MC, et al. (April 2016). "Sleep disorders and respiratory function in amyotrophic lateral sclerosis". Sleep Medicine Reviews. 26: 33–42. doi:10.1016/j.smrv.2015.05.007. PMID 26166297.
Eisen A, Krieger C (November 2013). "Ethical considerations in the management of amyotrophic lateral sclerosis". Progress in Neurobiology. 110: 45–53. doi:10.1016/j.pneurobio.2013.05.001. PMID 23735671. S2CID 26282198.
Lewis M, Rushanan S (2007). "The role of physical therapy and occupational therapy in the treatment of amyotrophic lateral sclerosis". NeuroRehabilitation. 22 (6): 451–461. doi:10.3233/NRE-2007-22608. PMID 18198431.
Orrell RW (2010). "Motor neuron disease: systematic reviews of treatment for ALS and SMA". British Medical Bulletin. 93: 145–159. doi:10.1093/bmb/ldp049. PMID 20015852.
Arbesman M, Sheard K (2014). "Systematic review of the effectiveness of occupational therapy-related interventions for people with amyotrophic lateral sclerosis". The American Journal of Occupational Therapy. 68 (1): 20–26. doi:10.5014/ajot.2014.008649. PMID 24367951.
Sulistyo A, Abrahao A, Freitas ME, Ritsma B, Zinman L (August 2023). "Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease". The Cochrane Database of Systematic Reviews. 2023 (8): CD004030. doi:10.1002/14651858.CD004030.pub4. PMC 10413437. PMID 37579081.
Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. (March 2012). "EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force". European Journal of Neurology. 19 (3): 360–375. doi:10.1111/j.1468-1331.2011.03501.x. PMID 21914052. S2CID 5746940.
Miller RG, Mitchell JD, Moore DH (March 2012). "Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)". The Cochrane Database of Systematic Reviews. 2012 (3): CD001447. doi:10.1002/14651858.CD001447.pub3. PMC 7055506. PMID 22419278.
Carlesi C, Pasquali L, Piazza S, Lo Gerfo A, Caldarazzo Ienco E, Alessi R, et al. (March 2011). "Strategies for clinical approach to neurodegeneration in Amyotrophic lateral sclerosis". Archives Italiennes de Biologie. 149 (1): 151–167. doi:10.4449/aib.v149i1.1267 (inactive 17 February 2025). PMID 21412722.{{cite journal}}: CS1 maint: DOI inactive as of February 2025 (link)
Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, et al. (July 2017). "Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial". The Lancet. Neurology. 16 (7): 505–512. doi:10.1016/S1474-4422(17)30115-1. PMID 28522181.
Dorst J, Ludolph AC, Huebers A (2018). "Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis". Therapeutic Advances in Neurological Disorders. 11: 1756285617734734. doi:10.1177/1756285617734734. PMC 5784546. PMID 29399045.
Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J (October 2017). "Edaravone and its clinical development for amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 18 (sup1): 5–10. doi:10.1080/21678421.2017.1353101. PMID 28872907.
Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. (September 2022). "Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS". The New England Journal of Medicine. 387 (12): 1099–1110. doi:10.1056/NEJMoa2204705. PMID 36129998. S2CID 252438252.
Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. (June 2015). "Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis". Neurology. 84 (22): 2247–2257. doi:10.1212/WNL.0000000000001642. PMC 4456658. PMID 25934855.
Liu X, Shang H, Wei Q, Yao X, Lian L, Dang J, et al. (24 February 2025). "Tetramethylpyrazine Nitrone in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial". JAMA Network Open. 8 (2): e2461055. doi:10.1001/jamanetworkopen.2024.61055. ISSN 2574-3805. PMC 11851239. PMID 39992655.
Paganoni S, Karam C, Joyce N, Bedlack R, Carter GT (2015). "Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis". NeuroRehabilitation. 37 (1): 53–68. doi:10.3233/NRE-151240. PMC 5223769. PMID 26409693.
Pinto S, Carvalho M (2014). "Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients". Neurodegenerative Disease Management. 4 (1): 83–102. doi:10.2217/nmt.13.74. PMID 24640982.
Majmudar S, Wu J, Paganoni S (July 2014). "Rehabilitation in amyotrophic lateral sclerosis: why it matters". Muscle & Nerve. 50 (1): 4–13. doi:10.1002/mus.24202. PMC 4433000. PMID 24510737.
Macpherson CE, Bassile CC (July 2016). "Pulmonary Physical Therapy Techniques to Enhance Survival in Amyotrophic Lateral Sclerosis: A Systematic Review". Journal of Neurologic Physical Therapy. 40 (3): 165–175. doi:10.1097/NPT.0000000000000136. PMID 27164308. S2CID 7279853.
Spataro R, Lo Re M, Piccoli T, Piccoli F, La Bella V (September 2010). "Causes and place of death in Italian patients with amyotrophic lateral sclerosis". Acta Neurologica Scandinavica. 122 (3): 217–223. doi:10.1111/j.1600-0404.2009.01290.x. PMID 20078446. S2CID 26479278.
Chiò A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. (2013). "Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature". Neuroepidemiology. 41 (2): 118–130. doi:10.1159/000351153. PMC 4049265. PMID 23860588.
Hardiman O, Al-Chalabi A, Brayne C, Beghi E, van den Berg LH, Chio A, et al. (July 2017). "The changing picture of amyotrophic lateral sclerosis: lessons from European registers". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (7): 557–563. doi:10.1136/jnnp-2016-314495. hdl:2318/1633611. PMID 28285264. S2CID 52871105. Archived from the original on 21 December 2019. Retrieved 22 August 2018.
Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. (November 2018). "Prevalence of Amyotrophic Lateral Sclerosis – United States, 2015". MMWR. Morbidity and Mortality Weekly Report. 67 (46): 1285–1289. doi:10.15585/mmwr.mm6746a1. PMC 5858037. PMID 30462626.
Arthur KC, Calvo A, Price TR, Geiger JT, Chiò A, Traynor BJ (August 2016). "Projected increase in amyotrophic lateral sclerosis from 2015 to 2040". Nature Communications. 7 (12408): 12408. Bibcode:2016NatCo...712408A. doi:10.1038/ncomms12408. PMC 4987527. PMID 27510634.
Luna J, Logroscino G, Couratier P, Marin B (May 2017). "Current issues in ALS epidemiology: Variation of ALS occurrence between populations and physical activity as a risk factor". Revue Neurologique. 173 (5): 244–253. doi:10.1016/j.neurol.2017.03.035. PMID 28477849.
Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP (July 2017). "Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (7): 540–549. doi:10.1136/jnnp-2016-315018. PMID 28057713. S2CID 41974606.
Teive HA, Lima PM, Germiniani FM, Munhoz RP (May 2016). "What's in a name? Problems, facts and controversies regarding neurological eponyms". Arquivos de Neuro-Psiquiatria. 74 (5): 423–425. doi:10.1590/0004-282X20160040. PMID 27191240.
Visser J, de Jong JM, de Visser M (February 2008). "The history of progressive muscular atrophy: syndrome or disease?". Neurology. 70 (9): 723–727. doi:10.1212/01.wnl.0000302187.20239.93. PMID 18299524. S2CID 22629725.
Wijesekera LC, Mathers S, Talman P, Galtrey C, Parkinson MH, Ganesalingam J, et al. (March 2009). "Natural history and clinical features of the flail arm and flail leg ALS variants". Neurology. 72 (12): 1087–1094. doi:10.1212/01.wnl.0000345041.83406.a2. PMC 2821838. PMID 19307543.
Wilbourn AJ (October 1998). "Clinical neurophysiology in the diagnosis of amyotrophic lateral sclerosis: the Lambert and the El Escorial criteria". Journal of the Neurological Sciences. 160 (Supplement 1): S25 – S29. doi:10.1016/s0022-510x(98)00194-4. PMID 9851644. S2CID 32884687.
Brooks BR (July 1994). "El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors". Journal of the Neurological Sciences. 124 (Supplement): 96–107. doi:10.1016/0022-510x(94)90191-0. PMID 7807156. S2CID 32678612.
Brooks BR, Miller RG, Swash M, Munsat TL (December 2000). "El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 1 (5): 293–299. doi:10.1080/146608200300079536. PMID 11464847. S2CID 22725949.
de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. (March 2008). "Electrodiagnostic criteria for diagnosis of ALS". Clinical Neurophysiology. 119 (3): 497–503. doi:10.1016/j.clinph.2007.09.143. PMID 18164242. S2CID 14851649.
Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A, et al. (August 2020). "A proposal for new diagnostic criteria for ALS". Clinical Neurophysiology. 131 (8): 1975–1978. doi:10.1016/j.clinph.2020.04.005. hdl:10451/48432. PMID 32387049. S2CID 215823371.
Goetz CG (March 2000). "Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot". Muscle & Nerve. 23 (3): 336–343. doi:10.1002/(SICI)1097-4598(200003)23:3<336::AID-MUS4>3.0.CO;2-L. PMID 10679709. S2CID 5917354.
Gordon PH (October 2013). "Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials". Aging and Disease. 4 (5): 295–310. doi:10.14336/AD.2013.0400295. PMC 3794725. PMID 24124634.
Huynh W, Simon NG, Grosskreutz J, Turner MR, Vucic S, Kiernan MC (July 2016). "Assessment of the upper motor neuron in amyotrophic lateral sclerosis". Clinical Neurophysiology. 127 (7): 2643–2660. doi:10.1016/j.clinph.2016.04.025. PMID 27291884. S2CID 3757685.
Wicks P (December 2014). "The ALS ice bucket challenge – can a splash of water reinvigorate a field?". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 15 (7–8): 479–480. doi:10.3109/21678421.2014.984725. PMID 25431828. S2CID 207581186.

elsevier.com

linkinghub.elsevier.com

Wang MD, Little J, Gomes J, Cashman NR, Krewski D (July 2017). "Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis". Neurotoxicology. 61: 101–130. Bibcode:2017NeuTx..61..101W. doi:10.1016/j.neuro.2016.06.015. PMID 27377857. S2CID 33604904. Archived from the original on 17 November 2022. Retrieved 27 May 2023.

fda.gov

Center for Drug Evaluation and Research (16 June 2022). "FDA Approves Oral Form for the treatment of adults with amyotrophic lateral sclerosis (ALS)". U.S. Food and Drug Administration. Archived from the original on 12 May 2022. Retrieved 25 April 2023.
"FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene" (Press release). U.S. Food and Drug Administration (FDA). 25 April 2023. Archived from the original on 25 April 2023. Retrieved 25 April 2023.

handle.net

hdl.handle.net

van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. (November 2017). "Amyotrophic lateral sclerosis". Lancet. 390 (10107): 2084–2098. doi:10.1016/S0140-6736(17)31287-4. hdl:2318/1673185. PMID 28552366. S2CID 24483077.
Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH (October 2016). "Amyotrophic lateral sclerosis: moving towards a new classification system". The Lancet. Neurology. 15 (11): 1182–1194. doi:10.1016/S1474-4422(16)30199-5. hdl:2318/1636249. PMID 27647646. S2CID 45285510.
Bede P, Oliver D, Stodart J, van den Berg L, Simmons Z, O Brannagáin D, et al. (April 2011). "Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives". Journal of Neurology, Neurosurgery, and Psychiatry. 82 (4): 413–418. doi:10.1136/jnnp.2010.232637. hdl:2262/59035. PMID 21297150. S2CID 7043837. Archived from the original on 28 May 2023. Retrieved 30 April 2023.
Renton AE, Chiò A, Traynor BJ (January 2014). "State of play in amyotrophic lateral sclerosis genetics". Nature Neuroscience. 17 (1): 17–23. doi:10.1038/nn.3584. hdl:2318/156177. PMC 4544832. PMID 24369373.
Nguyen HP, Van Broeckhoven C, van der Zee J (June 2018). "ALS Genes in the Genomic Era and their Implications for FTD". Trends in Genetics. 34 (6): 404–423. doi:10.1016/j.tig.2018.03.001. hdl:10067/1514730151162165141. PMID 29605155.
Hardiman O, Al-Chalabi A, Brayne C, Beghi E, van den Berg LH, Chio A, et al. (July 2017). "The changing picture of amyotrophic lateral sclerosis: lessons from European registers". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (7): 557–563. doi:10.1136/jnnp-2016-314495. hdl:2318/1633611. PMID 28285264. S2CID 52871105. Archived from the original on 21 December 2019. Retrieved 22 August 2018.
Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A, et al. (August 2020). "A proposal for new diagnostic criteria for ALS". Clinical Neurophysiology. 131 (8): 1975–1978. doi:10.1016/j.clinph.2020.04.005. hdl:10451/48432. PMID 32387049. S2CID 215823371.

harvard.edu

ui.adsabs.harvard.edu

Wingo TS, Cutler DJ, Yarab N, Kelly CM, Glass JD (2011). "The heritability of amyotrophic lateral sclerosis in a clinically ascertained United States research registry". PLOS ONE. 6 (11): e27985. Bibcode:2011PLoSO...627985W. doi:10.1371/journal.pone.0027985. PMC 3222666. PMID 22132186.
Wang MD, Little J, Gomes J, Cashman NR, Krewski D (July 2017). "Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis". Neurotoxicology. 61: 101–130. Bibcode:2017NeuTx..61..101W. doi:10.1016/j.neuro.2016.06.015. PMID 27377857. S2CID 33604904. Archived from the original on 17 November 2022. Retrieved 27 May 2023.
Vitturi BK, Montecucco A, Rahmani A, Dini G, Durando P (15 November 2023). "Occupational risk factors for multiple sclerosis: a systematic review with meta-analysis". Frontiers in Public Health. 11 (2023): Introduction. Bibcode:2023FrPH...1185103V. doi:10.3389/fpubh.2023.1285103. PMC 10694508. PMID 38054069.
Arthur KC, Calvo A, Price TR, Geiger JT, Chiò A, Traynor BJ (August 2016). "Projected increase in amyotrophic lateral sclerosis from 2015 to 2040". Nature Communications. 7 (12408): 12408. Bibcode:2016NatCo...712408A. doi:10.1038/ncomms12408. PMC 4987527. PMID 27510634.

independent.co.uk

Alexander E (20 August 2014). "George Bush delivers possibly the best ALS ice bucket challenge yet". The Independent. Archived from the original on 21 August 2014. Retrieved 20 August 2014.

kcl.ac.uk

kclpure.kcl.ac.uk

Brown RH, Al-Chalabi A (July 2017). "Amyotrophic Lateral Sclerosis". The New England Journal of Medicine. 377 (2): 162–172. doi:10.1056/NEJMra1603471. PMID 28700839. S2CID 205117619. Archived from the original on 25 February 2021. Retrieved 20 December 2019.
Hardiman O, Al-Chalabi A, Brayne C, Beghi E, van den Berg LH, Chio A, et al. (July 2017). "The changing picture of amyotrophic lateral sclerosis: lessons from European registers". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (7): 557–563. doi:10.1136/jnnp-2016-314495. hdl:2318/1633611. PMID 28285264. S2CID 52871105. Archived from the original on 21 December 2019. Retrieved 22 August 2018.

knowablemagazine.org

Dance A (17 June 2025). "How rogue jumping genes can spur Alzheimer's, ALS". doi:10.1146/knowable-061725-1. {{cite journal}}: Cite journal requires |journal= (help)

kuleuven.be

lirias.kuleuven.be

Swinnen B, Robberecht W (November 2014). "The phenotypic variability of amyotrophic lateral sclerosis". Nature Reviews. Neurology. 10 (11): 661–670. doi:10.1038/nrneurol.2014.184. PMID 25311585. S2CID 205516010. Archived from the original on 31 December 2018. Retrieved 22 August 2018.

lems.com

"Lambert-Eaton Myasthenic Syndrome: About". LEMS.com. BioMarin Pharmaceutical Inc. Archived from the original on 20 January 2013. Retrieved 18 April 2013.

mayoclinic.org

"Amyotrophic lateral sclerosis (ALS) - Symptoms and causes". Mayo Clinic. Archived from the original on 6 April 2022. Retrieved 6 April 2022.

mda.org

"ALS: Amyotrophic Lateral Sclerosis". Muscular Dystrophy Association. 18 December 2015. Archived from the original on 6 August 2018. Retrieved 23 December 2018.

medlineplus.gov

"Amyotrophic lateral sclerosis". MedlinePlus Genetics. Retrieved 7 August 2023.

medpagetoday.com

"Novel Agent Safe in ALS, Phase II Study Suggests". 28 February 2025.

medscape.com

misc.medscape.com

Stickler DE. Lorenzo N (ed.). "Lambert-Eaton Myasthenic Syndrome (LEMS)". Misc.medscape.com. Archived from the original on 14 May 2013. Retrieved 18 April 2013.

nhs.uk

"Motor neurone disease". UK: National Health Service. 15 January 2018. Archived from the original on 29 December 2014. Retrieved 24 October 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Wijesekera LC, Leigh PN (February 2009). "Amyotrophic lateral sclerosis". Orphanet Journal of Rare Diseases. 4 (4): 3. doi:10.1186/1750-1172-4-3. PMC 2656493. PMID 19192301.
Masrori P, Van Damme P (October 2020). "Amyotrophic lateral sclerosis: a clinical review". European Journal of Neurology. 27 (10): 1918–1929. doi:10.1111/ene.14393. PMC 7540334. PMID 32526057.
Kwan J, Vullaganti M (September 2022). "Amyotrophic lateral sclerosis mimics". Muscle & Nerve. 66 (3): 240–252. doi:10.1002/mus.27567. PMID 35607838. S2CID 249014375.
Hobson EV, McDermott CJ (September 2016). "Supportive and symptomatic management of amyotrophic lateral sclerosis" (PDF). Nature Reviews. Neurology. 12 (9): 526–538. doi:10.1038/nrneurol.2016.111. PMID 27514291. S2CID 8547381. Archived (PDF) from the original on 1 December 2020. Retrieved 20 December 2019.
Goutman SA, Hardiman O, Al-Chalabi A, Chió A, Savelieff MG, Kiernan MC, et al. (May 2022). "Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis". The Lancet. Neurology. 21 (5): 480–493. doi:10.1016/S1474-4422(21)00465-8. PMC 9513753. PMID 35334233.
Ryan M, Heverin M, McLaughlin RL, Hardiman O (November 2019). "Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis". JAMA Neurology. 76 (11): 1367–1374. doi:10.1001/jamaneurol.2019.2044. PMC 6646974. PMID 31329211.
van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. (November 2017). "Amyotrophic lateral sclerosis". Lancet. 390 (10107): 2084–2098. doi:10.1016/S0140-6736(17)31287-4. hdl:2318/1673185. PMID 28552366. S2CID 24483077.
Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. (October 2017). "Amyotrophic lateral sclerosis" (PDF). Nature Reviews. Disease Primers. 3 (17071): 17071. doi:10.1038/nrdp.2017.71. PMID 28980624. S2CID 1002680. Archived (PDF) from the original on 1 December 2020. Retrieved 20 December 2019.
Wingo TS, Cutler DJ, Yarab N, Kelly CM, Glass JD (2011). "The heritability of amyotrophic lateral sclerosis in a clinically ascertained United States research registry". PLOS ONE. 6 (11): e27985. Bibcode:2011PLoSO...627985W. doi:10.1371/journal.pone.0027985. PMC 3222666. PMID 22132186.
Goutman SA, Hardiman O, Al-Chalabi A, Chió A, Savelieff MG, Kiernan MC, et al. (May 2022). "Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis". The Lancet. Neurology. 21 (5): 465–479. doi:10.1016/S1474-4422(21)00414-2. PMC 9513754. PMID 35334234.
Soriani MH, Desnuelle C (May 2017). "Care management in amyotrophic lateral sclerosis". Revue Neurologique. 173 (5): 288–299. doi:10.1016/j.neurol.2017.03.031. PMID 28461024.
Connolly S, Galvin M, Hardiman O (April 2015). "End-of-life management in patients with amyotrophic lateral sclerosis". The Lancet. Neurology. 14 (4): 435–442. doi:10.1016/S1474-4422(14)70221-2. PMID 25728958. S2CID 34109901.
Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. (March 2011). "Amyotrophic lateral sclerosis". Lancet. 377 (9769): 942–955. doi:10.1016/s0140-6736(10)61156-7. PMID 21296405.
Pupillo E, Messina P, Logroscino G, Beghi E (February 2014). "Long-term survival in amyotrophic lateral sclerosis: a population-based study". Annals of Neurology. 75 (2): 287–297. doi:10.1002/ana.24096. PMID 24382602. S2CID 205345019.
Rowland LP (March 2001). "How amyotrophic lateral sclerosis got its name: the clinical-pathologic genius of Jean-Martin Charcot". Archives of Neurology. 58 (3): 512–515. doi:10.1001/archneur.58.3.512. PMID 11255459.
van Eenennaam RM, Koppenol LS, Kruithof WJ, Kruitwagen-van Reenen ET, Pieters S, van Es MA, et al. (November 2021). "Discussing Personalized Prognosis Empowers Patients with Amyotrophic Lateral Sclerosis to Regain Control over Their Future: A Qualitative Study". Brain Sciences. 11 (12): 1597. doi:10.3390/brainsci11121597. PMC 8699408. PMID 34942899.
Grad LI, Rouleau GA, Ravits J, Cashman NR (August 2017). "Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS)". Cold Spring Harbor Perspectives in Medicine. 7 (8): a024117. doi:10.1101/cshperspect.a024117. PMC 5538408. PMID 28003278.
Arora RD, Khan YS (2023). "Motor Neuron Disease". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32809609. Retrieved 27 August 2023.
Gautier G, Verschueren A, Monnier A, Attarian S, Salort-Campana E, Pouget J (August 2010). "ALS with respiratory onset: clinical features and effects of non-invasive ventilation on the prognosis". Amyotrophic Lateral Sclerosis. 11 (4): 379–382. doi:10.3109/17482960903426543. PMID 20001486. S2CID 27672209.
Swinnen B, Robberecht W (November 2014). "The phenotypic variability of amyotrophic lateral sclerosis". Nature Reviews. Neurology. 10 (11): 661–670. doi:10.1038/nrneurol.2014.184. PMID 25311585. S2CID 205516010. Archived from the original on 31 December 2018. Retrieved 22 August 2018.
Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH (October 2016). "Amyotrophic lateral sclerosis: moving towards a new classification system". The Lancet. Neurology. 15 (11): 1182–1194. doi:10.1016/S1474-4422(16)30199-5. hdl:2318/1636249. PMID 27647646. S2CID 45285510.
Jawdat O, Statland JM, Barohn RJ, Katz JS, Dimachkie MM (November 2015). "Amyotrophic Lateral Sclerosis Regional Variants (Brachial Amyotrophic Diplegia, Leg Amyotrophic Diplegia, and Isolated Bulbar Amyotrophic Lateral Sclerosis)". Neurologic Clinics. 33 (4): 775–785. doi:10.1016/j.ncl.2015.07.003. PMC 4629514. PMID 26515621.
Zhang H, Chen L, Tian J, Fan D (October 2021). "Disease duration of progression is helpful in identifying isolated bulbar palsy of amyotrophic lateral sclerosis". BMC Neurology. 21 (1): 405. doi:10.1186/s12883-021-02438-8. PMC 8532334. PMID 34686150.
Mehta PR, Jones AR, Opie-Martin S, Shatunov A, Iacoangeli A, Khleifat AA, et al. (1 March 2019). "Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias". Journal of Neurology, Neurosurgery & Psychiatry. 90 (3): 268–271. doi:10.1136/jnnp-2018-319089. ISSN 0022-3050. PMC 6518463. PMID 30270202.
Lehky T, Grunseich C (November 2021). "Juvenile Amyotrophic Lateral Sclerosis: A Review". Genes. 12 (12): 1935. doi:10.3390/genes12121935. PMC 8701111. PMID 34946884.
Teoh HL, Carey K, Sampaio H, Mowat D, Roscioli T, Farrar M (2017). "Inherited Paediatric Motor Neuron Disorders: Beyond Spinal Muscular Atrophy". Neural Plasticity. 2017: 6509493. doi:10.1155/2017/6509493. PMC 5467325. PMID 28634552.
Tard C, Defebvre L, Moreau C, Devos D, Danel-Brunaud V (May 2017). "Clinical features of amyotrophic lateral sclerosis and their prognostic value". Revue Neurologique. 173 (5): 263–272. doi:10.1016/j.neurol.2017.03.029. PMID 28477850.
Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L, et al. (May 2013). "Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 14 (Suppl 1): 5–18. doi:10.3109/21678421.2013.778548. PMC 3779649. PMID 23678876.
Chiò A, Mora G, Lauria G (February 2017). "Pain in amyotrophic lateral sclerosis". The Lancet. Neurology. 16 (2): 144–157. arXiv:1607.02870. doi:10.1016/S1474-4422(16)30358-1. PMID 27964824. S2CID 38905437.
Gromicho M, Figueiral M, Uysal H, Grosskreutz J, Kuzma-Kozakiewicz M, Pinto S, et al. (July 2020). "Spreading in ALS: The relative impact of upper and lower motor neuron involvement". Annals of Clinical and Translational Neurology. 7 (7): 1181–1192. doi:10.1002/acn3.51098. PMC 7359118. PMID 32558369.
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. (October 1999). "The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)". Journal of the Neurological Sciences. 169 (1–2): 13–21. doi:10.1016/s0022-510x(99)00210-5. PMID 10540002. S2CID 7057926.
Wong C, Stavrou M, Elliott E, Gregory JM, Leigh N, Pinto AA, et al. (2021). "Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective". Brain Communications. 3 (4): fcab242. doi:10.1093/braincomms/fcab242. PMC 8659356. PMID 34901853.
Creemers H, Grupstra H, Nollet F, van den Berg LH, Beelen A (June 2015). "Prognostic factors for the course of functional status of patients with ALS: a systematic review". Journal of Neurology. 262 (6): 1407–1423. doi:10.1007/s00415-014-7564-8. PMID 25385051. S2CID 31734765.
Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. (November 2014). "The PRO-ACT database: design, initial analyses, and predictive features". Neurology. 83 (19): 1719–1725. doi:10.1212/WNL.0000000000000951. PMC 4239834. PMID 25298304.
Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, et al. (March 2016). "How common are ALS plateaus and reversals?". Neurology. 86 (9): 808–812. doi:10.1212/WNL.0000000000002251. PMC 4793781. PMID 26658909.
Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME (2010). "Clinical significance in the change of decline in ALSFRS-R". Amyotrophic Lateral Sclerosis (Journal Article). 11 (1–2): 178–180. doi:10.3109/17482960903093710. PMID 19634063. S2CID 207619689.
Yunusova Y, Plowman EK, Green JR, Barnett C, Bede P (2019). "Clinical Measures of Bulbar Dysfunction in ALS". Frontiers in Neurology. 10: 106. doi:10.3389/fneur.2019.00106. PMC 6389633. PMID 30837936.
Lui AJ, Byl NN (June 2009). "A systematic review of the effect of moderate intensity exercise on function and disease progression in amyotrophic lateral sclerosis". Journal of Neurologic Physical Therapy. 33 (2): 68–87. doi:10.1097/NPT.0b013e31819912d0. PMID 19556916. S2CID 7650356.
Beukelman D, Fager S, Nordness A (2011). "Communication Support for People with ALS". Neurology Research International. 2011: 714693. doi:10.1155/2011/714693. PMC 3096454. PMID 21603029.
Kuzma-Kozakiewicz M, Andersen PM, Ciecwierska K, Vázquez C, Helczyk O, Loose M, et al. (September 2019). "An observational study on quality of life and preferences to sustain life in locked-in state". Neurology. 93 (10): e938 – e945. doi:10.1212/WNL.0000000000008064. PMC 6745736. PMID 31391247.
O'Brien D, Stavroulakis T, Baxter S, Norman P, Bianchi S, Elliott M, et al. (September 2019). "The optimisation of noninvasive ventilation in amyotrophic lateral sclerosis: a systematic review". The European Respiratory Journal. 54 (3): 1900261. doi:10.1183/13993003.00261-2019. PMID 31273038. S2CID 195805546.
Bede P, Oliver D, Stodart J, van den Berg L, Simmons Z, O Brannagáin D, et al. (April 2011). "Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives". Journal of Neurology, Neurosurgery, and Psychiatry. 82 (4): 413–418. doi:10.1136/jnnp.2010.232637. hdl:2262/59035. PMID 21297150. S2CID 7043837. Archived from the original on 28 May 2023. Retrieved 30 April 2023.
Corcia P, Pradat PF, Salachas F, Bruneteau G, Forestier N, Seilhean D, et al. (1 January 2008). "Causes of death in a post-mortem series of ALS patients". Amyotrophic Lateral Sclerosis. 9 (1): 59–62. doi:10.1080/17482960701656940. PMID 17924236. S2CID 40367873.
Fang T, Al Khleifat A, Stahl DR, Lazo La Torre C, Murphy C, Young C, et al. (May 2017). "Comparison of the King's and MiToS staging systems for ALS". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 18 (3–4): 227–232. doi:10.1080/21678421.2016.1265565. PMC 5425622. PMID 28054828.
Chiò A, Calvo A, Moglia C, Mazzini L, Mora G (July 2011). "Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study" (PDF). Journal of Neurology, Neurosurgery, and Psychiatry. 82 (7): 740–746. doi:10.1136/jnnp.2010.235952. PMID 21402743. S2CID 13416164. Archived (PDF) from the original on 24 November 2022. Retrieved 4 August 2022.
Martin S, Al Khleifat A, Al-Chalabi A (2017). "What causes amyotrophic lateral sclerosis?". F1000Research. 6: 371. doi:10.12688/f1000research.10476.1. PMC 5373425. PMID 28408982.
Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, et al. (October 2018). "ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS". Neurology. 91 (15): e1370 – e1380. doi:10.1212/WNL.0000000000006317. PMC 6177274. PMID 30209236.
Yang T, Hou Y, Li C, Cao B, Cheng Y, Wei Q, et al. (July 2021). "Risk factors for cognitive impairment in amyotrophic lateral sclerosis: a systematic review and meta-analysis". Journal of Neurology, Neurosurgery, and Psychiatry. 92 (7): 688–693. doi:10.1136/jnnp-2020-325701. PMID 33563800. S2CID 231858696.
Wicks P (July 2007). "Excessive yawning is common in the bulbar-onset form of ALS". Acta Psychiatrica Scandinavica. 116 (1): 76, author reply 76–76, author reply 77. doi:10.1111/j.1600-0447.2007.01025.x. PMID 17559605. S2CID 12807996.
Sauvé WM (December 2016). "Recognizing and treating pseudobulbar affect". CNS Spectrums. 21 (S1): 34–44. doi:10.1017/S1092852916000791. PMID 28044945. S2CID 21066800.
Raaphorst J, Beeldman E, De Visser M, De Haan RJ, Schmand B (October 2012). "A systematic review of behavioural changes in motor neuron disease". Amyotrophic Lateral Sclerosis. 13 (6): 493–501. doi:10.3109/17482968.2012.656652. PMID 22424127. S2CID 22224140.
Couratier P, Corcia P, Lautrette G, Nicol M, Marin B (May 2017). "ALS and frontotemporal dementia belong to a common disease spectrum". Revue Neurologique. 173 (5): 273–279. doi:10.1016/j.neurol.2017.04.001. PMID 28449882.
Renton AE, Chiò A, Traynor BJ (January 2014). "State of play in amyotrophic lateral sclerosis genetics". Nature Neuroscience. 17 (1): 17–23. doi:10.1038/nn.3584. hdl:2318/156177. PMC 4544832. PMID 24369373.
Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, de Haan RJ (June 2016). "The cognitive profile of ALS: a systematic review and meta-analysis update". Journal of Neurology, Neurosurgery, and Psychiatry. 87 (6): 611–619. doi:10.1136/jnnp-2015-310734. PMID 26283685. S2CID 22082109.
Al-Chalabi A, Hardiman O (November 2013). "The epidemiology of ALS: a conspiracy of genes, environment and time". Nature Reviews. Neurology. 9 (11): 617–628. doi:10.1038/nrneurol.2013.203. PMID 24126629. S2CID 25040863.
He J, Mangelsdorf M, Fan D, Bartlett P, Brown MA (December 2015). "Amyotrophic Lateral Sclerosis Genetic Studies: From Genome-wide Association Mapping to Genome Sequencing" (PDF). The Neuroscientist. 21 (6): 599–615. doi:10.1177/1073858414555404. PMID 25378359. S2CID 3437565. Archived (PDF) from the original on 7 May 2020. Retrieved 20 December 2019.
McNeill A, Amador MD, Bekker H, Clarke A, Crook A, Cummings C, et al. (June 2022). "Predictive genetic testing for Motor neuron disease: time for a guideline?". European Journal of Human Genetics. 30 (6): 635–636. doi:10.1038/s41431-022-01093-y. PMC 9177585. PMID 35379930.
De Oliveira HM, Soma A, Baker MR, Turner MR, Talbot K, Williams TL (August 2023). "A survey of current practice in genetic testing in amyotrophic lateral sclerosis in the UK and Republic of Ireland: implications for future planning". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 24 (5–6): 405–413. doi:10.1080/21678421.2022.2150556. PMID 36458618. S2CID 254150195.
Müller K, Oh KW, Nordin A, Panthi S, Kim SH, Nordin F, et al. (February 2022). "De novo mutations in SOD1 are a cause of ALS". Journal of Neurology, Neurosurgery, and Psychiatry. 93 (2): 201–206. doi:10.1136/jnnp-2021-327520. PMC 8784989. PMID 34518333.
Mehta PR, Iacoangeli A, Opie-Martin S, van Vugt JJ, Al Khleifat A, Bredin A, et al. (19 December 2022). "The impact of age on genetic testing decisions in amyotrophic lateral sclerosis". Brain. 145 (12): 4440–4447. doi:10.1093/brain/awac279. ISSN 0006-8950. PMC 9762932. PMID 36162820.
Salmon K, Kiernan MC, Kim SH, Andersen PM, Chio A, van den Berg LH, et al. (May 2022). "The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis". Brain. 145 (4): 1207–1210. doi:10.1093/brain/awab472. PMC 9129091. PMID 35020823. Archived from the original on 27 May 2023. Retrieved 27 May 2023.
Wang MD, Little J, Gomes J, Cashman NR, Krewski D (July 2017). "Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis". Neurotoxicology. 61: 101–130. Bibcode:2017NeuTx..61..101W. doi:10.1016/j.neuro.2016.06.015. PMID 27377857. S2CID 33604904. Archived from the original on 17 November 2022. Retrieved 27 May 2023.
Vitturi BK, Montecucco A, Rahmani A, Dini G, Durando P (15 November 2023). "Occupational risk factors for multiple sclerosis: a systematic review with meta-analysis". Frontiers in Public Health. 11 (2023): Introduction. Bibcode:2023FrPH...1185103V. doi:10.3389/fpubh.2023.1285103. PMC 10694508. PMID 38054069.
Grossman AB, Levin BE, Bradley WG (March 2006). "Premorbid personality characteristics of patients with ALS". Amyotrophic Lateral Sclerosis. 7 (1): 27–31. doi:10.1080/14660820510012004. PMID 16546756. S2CID 20998807.
Parkin Kullmann JA, Hayes S, Pamphlett R (October 2018). "Are people with amyotrophic lateral sclerosis (ALS) particularly nice? An international online case-control study of the Big Five personality factors". Brain and Behavior. 8 (10): e01119. doi:10.1002/brb3.1119. PMC 6192405. PMID 30239176.
Mehl T, Jordan B, Zierz S (January 2017). ""Patients with amyotrophic lateral sclerosis (ALS) are usually nice persons"-How physicians experienced in ALS see the personality characteristics of their patients". Brain and Behavior. 7 (1): e00599. doi:10.1002/brb3.599. PMC 5256182. PMID 28127517.
Robberecht W, Philips T (April 2013). "The changing scene of amyotrophic lateral sclerosis". Nature Reviews. Neuroscience. 14 (4): 248–264. doi:10.1038/nrn3430. PMID 23463272. S2CID 208941.
Brown RH, Al-Chalabi A (July 2017). "Amyotrophic Lateral Sclerosis". The New England Journal of Medicine. 377 (2): 162–172. doi:10.1056/NEJMra1603471. PMID 28700839. S2CID 205117619. Archived from the original on 25 February 2021. Retrieved 20 December 2019.
Okamoto K, Mizuno Y, Fujita Y (April 2008). "Bunina bodies in amyotrophic lateral sclerosis". Neuropathology. 28 (2): 109–115. doi:10.1111/j.1440-1789.2007.00873.x. PMID 18069968. S2CID 34398467.
White JA, Banerjee R, Gunawardena S (May 2016). "Axonal Transport and Neurodegeneration: How Marine Drugs Can Be Used for the Development of Therapeutics". Marine Drugs. 14 (5): 102. doi:10.3390/md14050102. PMC 4882576. PMID 27213408.
Ng Kee Kwong KC, Mehta AR, Nedergaard M, Chandran S (August 2020). "Defining novel functions for cerebrospinal fluid in ALS pathophysiology". Acta Neuropathologica Communications. 8 (1): 140. doi:10.1186/s40478-020-01018-0. PMC 7439665. PMID 32819425.
Van Damme P, Robberecht W, Van Den Bosch L (May 2017). "Modelling amyotrophic lateral sclerosis: progress and possibilities". Disease Models & Mechanisms. 10 (5): 537–549. doi:10.1242/dmm.029058. PMC 5451175. PMID 28468939.
Alsultan AA, Waller R, Heath PR, Kirby J (2016). "The genetics of amyotrophic lateral sclerosis: current insights". Degenerative Neurological and Neuromuscular Disease. 6: 49–64. doi:10.2147/DNND.S84956. PMC 6053097. PMID 30050368.
Shang Y, Huang EJ (September 2016). "Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis". Brain Research. 1647: 65–78. doi:10.1016/j.brainres.2016.03.036. PMC 5003642. PMID 27033831.
Mehta PR, Brown AL, Ward ME, Fratta P (15 March 2023). "The era of cryptic exons: implications for ALS-FTD". Molecular Neurodegeneration. 18 (1): 16. doi:10.1186/s13024-023-00608-5. ISSN 1750-1326. PMC 10018954. PMID 36922834.
Nguyen HP, Van Broeckhoven C, van der Zee J (June 2018). "ALS Genes in the Genomic Era and their Implications for FTD". Trends in Genetics. 34 (6): 404–423. doi:10.1016/j.tig.2018.03.001. hdl:10067/1514730151162165141. PMID 29605155.
Gitler AD, Tsuiji H (September 2016). "There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS". Brain Research. 1647: 19–29. doi:10.1016/j.brainres.2016.04.004. PMC 5003651. PMID 27059391.
Mehta AR, Gregory JM, Dando O, Carter RN, Burr K, Nanda J, et al. (February 2021). "Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis". Acta Neuropathologica. 141 (2): 257–279. doi:10.1007/s00401-020-02252-5. PMC 7847443. PMID 33398403.
Verber NS, Shepheard SR, Sassani M, McDonough HE, Moore SA, Alix JJ, et al. (2019). "Biomarkers in Motor Neuron Disease: A State of the Art Review". Frontiers in Neurology. 10: 291. doi:10.3389/fneur.2019.00291. PMC 6456669. PMID 31001186.
Joyce NC, Carter GT (May 2013). "Electrodiagnosis in persons with amyotrophic lateral sclerosis". PM&R. 5 (5 Suppl): S89 – S95. doi:10.1016/j.pmrj.2013.03.020. PMC 4590769. PMID 23523708.
Silani V, Messina S, Poletti B, Morelli C, Doretti A, Ticozzi N, et al. (March 2011). "The diagnosis of Amyotrophic lateral sclerosis in 2010". Archives Italiennes de Biologie. 149 (1): 5–27. doi:10.4449/aib.v149i1.1260 (inactive 22 January 2025). PMID 21412713.{{cite journal}}: CS1 maint: DOI inactive as of January 2025 (link)
Mills KR (November 2010). "Characteristics of fasciculations in amyotrophic lateral sclerosis and the benign fasciculation syndrome". Brain. 133 (11): 3458–3469. doi:10.1093/brain/awq290. PMID 20959307.
Radunovic A, Annane D, Rafiq MK, Brassington R, Mustfa N (October 2017). "Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease". The Cochrane Database of Systematic Reviews. 10 (10): CD004427. doi:10.1002/14651858.CD004427.pub4. PMC 6485636. PMID 28982219.
Ahmed RM, Newcombe RE, Piper AJ, Lewis SJ, Yee BJ, Kiernan MC, et al. (April 2016). "Sleep disorders and respiratory function in amyotrophic lateral sclerosis". Sleep Medicine Reviews. 26: 33–42. doi:10.1016/j.smrv.2015.05.007. PMID 26166297.
Eisen A, Krieger C (November 2013). "Ethical considerations in the management of amyotrophic lateral sclerosis". Progress in Neurobiology. 110: 45–53. doi:10.1016/j.pneurobio.2013.05.001. PMID 23735671. S2CID 26282198.
Lewis M, Rushanan S (2007). "The role of physical therapy and occupational therapy in the treatment of amyotrophic lateral sclerosis". NeuroRehabilitation. 22 (6): 451–461. doi:10.3233/NRE-2007-22608. PMID 18198431.
Orrell RW (2010). "Motor neuron disease: systematic reviews of treatment for ALS and SMA". British Medical Bulletin. 93: 145–159. doi:10.1093/bmb/ldp049. PMID 20015852.
Arbesman M, Sheard K (2014). "Systematic review of the effectiveness of occupational therapy-related interventions for people with amyotrophic lateral sclerosis". The American Journal of Occupational Therapy. 68 (1): 20–26. doi:10.5014/ajot.2014.008649. PMID 24367951.
Sulistyo A, Abrahao A, Freitas ME, Ritsma B, Zinman L (August 2023). "Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease". The Cochrane Database of Systematic Reviews. 2023 (8): CD004030. doi:10.1002/14651858.CD004030.pub4. PMC 10413437. PMID 37579081.
Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. (March 2012). "EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force". European Journal of Neurology. 19 (3): 360–375. doi:10.1111/j.1468-1331.2011.03501.x. PMID 21914052. S2CID 5746940.
Miller RG, Mitchell JD, Moore DH (March 2012). "Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)". The Cochrane Database of Systematic Reviews. 2012 (3): CD001447. doi:10.1002/14651858.CD001447.pub3. PMC 7055506. PMID 22419278.
Carlesi C, Pasquali L, Piazza S, Lo Gerfo A, Caldarazzo Ienco E, Alessi R, et al. (March 2011). "Strategies for clinical approach to neurodegeneration in Amyotrophic lateral sclerosis". Archives Italiennes de Biologie. 149 (1): 151–167. doi:10.4449/aib.v149i1.1267 (inactive 17 February 2025). PMID 21412722.{{cite journal}}: CS1 maint: DOI inactive as of February 2025 (link)
Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M, et al. (July 2017). "Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial". The Lancet. Neurology. 16 (7): 505–512. doi:10.1016/S1474-4422(17)30115-1. PMID 28522181.
Dorst J, Ludolph AC, Huebers A (2018). "Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis". Therapeutic Advances in Neurological Disorders. 11: 1756285617734734. doi:10.1177/1756285617734734. PMC 5784546. PMID 29399045.
Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J (October 2017). "Edaravone and its clinical development for amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 18 (sup1): 5–10. doi:10.1080/21678421.2017.1353101. PMID 28872907.
Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. (September 2022). "Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS". The New England Journal of Medicine. 387 (12): 1099–1110. doi:10.1056/NEJMoa2204705. PMID 36129998. S2CID 252438252.
Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. (June 2015). "Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis". Neurology. 84 (22): 2247–2257. doi:10.1212/WNL.0000000000001642. PMC 4456658. PMID 25934855.
Liu X, Shang H, Wei Q, Yao X, Lian L, Dang J, et al. (24 February 2025). "Tetramethylpyrazine Nitrone in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial". JAMA Network Open. 8 (2): e2461055. doi:10.1001/jamanetworkopen.2024.61055. ISSN 2574-3805. PMC 11851239. PMID 39992655.
Paganoni S, Karam C, Joyce N, Bedlack R, Carter GT (2015). "Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis". NeuroRehabilitation. 37 (1): 53–68. doi:10.3233/NRE-151240. PMC 5223769. PMID 26409693.
Pinto S, Carvalho M (2014). "Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients". Neurodegenerative Disease Management. 4 (1): 83–102. doi:10.2217/nmt.13.74. PMID 24640982.
Majmudar S, Wu J, Paganoni S (July 2014). "Rehabilitation in amyotrophic lateral sclerosis: why it matters". Muscle & Nerve. 50 (1): 4–13. doi:10.1002/mus.24202. PMC 4433000. PMID 24510737.
Macpherson CE, Bassile CC (July 2016). "Pulmonary Physical Therapy Techniques to Enhance Survival in Amyotrophic Lateral Sclerosis: A Systematic Review". Journal of Neurologic Physical Therapy. 40 (3): 165–175. doi:10.1097/NPT.0000000000000136. PMID 27164308. S2CID 7279853.
Spataro R, Lo Re M, Piccoli T, Piccoli F, La Bella V (September 2010). "Causes and place of death in Italian patients with amyotrophic lateral sclerosis". Acta Neurologica Scandinavica. 122 (3): 217–223. doi:10.1111/j.1600-0404.2009.01290.x. PMID 20078446. S2CID 26479278.
Chiò A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. (2013). "Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature". Neuroepidemiology. 41 (2): 118–130. doi:10.1159/000351153. PMC 4049265. PMID 23860588.
Hardiman O, Al-Chalabi A, Brayne C, Beghi E, van den Berg LH, Chio A, et al. (July 2017). "The changing picture of amyotrophic lateral sclerosis: lessons from European registers". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (7): 557–563. doi:10.1136/jnnp-2016-314495. hdl:2318/1633611. PMID 28285264. S2CID 52871105. Archived from the original on 21 December 2019. Retrieved 22 August 2018.
Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. (November 2018). "Prevalence of Amyotrophic Lateral Sclerosis – United States, 2015". MMWR. Morbidity and Mortality Weekly Report. 67 (46): 1285–1289. doi:10.15585/mmwr.mm6746a1. PMC 5858037. PMID 30462626.
Arthur KC, Calvo A, Price TR, Geiger JT, Chiò A, Traynor BJ (August 2016). "Projected increase in amyotrophic lateral sclerosis from 2015 to 2040". Nature Communications. 7 (12408): 12408. Bibcode:2016NatCo...712408A. doi:10.1038/ncomms12408. PMC 4987527. PMID 27510634.
Luna J, Logroscino G, Couratier P, Marin B (May 2017). "Current issues in ALS epidemiology: Variation of ALS occurrence between populations and physical activity as a risk factor". Revue Neurologique. 173 (5): 244–253. doi:10.1016/j.neurol.2017.03.035. PMID 28477849.
Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP (July 2017). "Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (7): 540–549. doi:10.1136/jnnp-2016-315018. PMID 28057713. S2CID 41974606.
Teive HA, Lima PM, Germiniani FM, Munhoz RP (May 2016). "What's in a name? Problems, facts and controversies regarding neurological eponyms". Arquivos de Neuro-Psiquiatria. 74 (5): 423–425. doi:10.1590/0004-282X20160040. PMID 27191240.
Visser J, de Jong JM, de Visser M (February 2008). "The history of progressive muscular atrophy: syndrome or disease?". Neurology. 70 (9): 723–727. doi:10.1212/01.wnl.0000302187.20239.93. PMID 18299524. S2CID 22629725.
Wijesekera LC, Mathers S, Talman P, Galtrey C, Parkinson MH, Ganesalingam J, et al. (March 2009). "Natural history and clinical features of the flail arm and flail leg ALS variants". Neurology. 72 (12): 1087–1094. doi:10.1212/01.wnl.0000345041.83406.a2. PMC 2821838. PMID 19307543.
Wilbourn AJ (October 1998). "Clinical neurophysiology in the diagnosis of amyotrophic lateral sclerosis: the Lambert and the El Escorial criteria". Journal of the Neurological Sciences. 160 (Supplement 1): S25 – S29. doi:10.1016/s0022-510x(98)00194-4. PMID 9851644. S2CID 32884687.
Brooks BR (July 1994). "El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors". Journal of the Neurological Sciences. 124 (Supplement): 96–107. doi:10.1016/0022-510x(94)90191-0. PMID 7807156. S2CID 32678612.
Brooks BR, Miller RG, Swash M, Munsat TL (December 2000). "El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 1 (5): 293–299. doi:10.1080/146608200300079536. PMID 11464847. S2CID 22725949.
de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. (March 2008). "Electrodiagnostic criteria for diagnosis of ALS". Clinical Neurophysiology. 119 (3): 497–503. doi:10.1016/j.clinph.2007.09.143. PMID 18164242. S2CID 14851649.
Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A, et al. (August 2020). "A proposal for new diagnostic criteria for ALS". Clinical Neurophysiology. 131 (8): 1975–1978. doi:10.1016/j.clinph.2020.04.005. hdl:10451/48432. PMID 32387049. S2CID 215823371.
Goetz CG (March 2000). "Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot". Muscle & Nerve. 23 (3): 336–343. doi:10.1002/(SICI)1097-4598(200003)23:3<336::AID-MUS4>3.0.CO;2-L. PMID 10679709. S2CID 5917354.
Gordon PH (October 2013). "Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials". Aging and Disease. 4 (5): 295–310. doi:10.14336/AD.2013.0400295. PMC 3794725. PMID 24124634.
Huynh W, Simon NG, Grosskreutz J, Turner MR, Vucic S, Kiernan MC (July 2016). "Assessment of the upper motor neuron in amyotrophic lateral sclerosis". Clinical Neurophysiology. 127 (7): 2643–2660. doi:10.1016/j.clinph.2016.04.025. PMID 27291884. S2CID 3757685.
Wicks P (December 2014). "The ALS ice bucket challenge – can a splash of water reinvigorate a field?". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 15 (7–8): 479–480. doi:10.3109/21678421.2014.984725. PMID 25431828. S2CID 207581186.

ncbi.nlm.nih.gov

Wijesekera LC, Leigh PN (February 2009). "Amyotrophic lateral sclerosis". Orphanet Journal of Rare Diseases. 4 (4): 3. doi:10.1186/1750-1172-4-3. PMC 2656493. PMID 19192301.
Masrori P, Van Damme P (October 2020). "Amyotrophic lateral sclerosis: a clinical review". European Journal of Neurology. 27 (10): 1918–1929. doi:10.1111/ene.14393. PMC 7540334. PMID 32526057.
Goutman SA, Hardiman O, Al-Chalabi A, Chió A, Savelieff MG, Kiernan MC, et al. (May 2022). "Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis". The Lancet. Neurology. 21 (5): 480–493. doi:10.1016/S1474-4422(21)00465-8. PMC 9513753. PMID 35334233.
Ryan M, Heverin M, McLaughlin RL, Hardiman O (November 2019). "Lifetime Risk and Heritability of Amyotrophic Lateral Sclerosis". JAMA Neurology. 76 (11): 1367–1374. doi:10.1001/jamaneurol.2019.2044. PMC 6646974. PMID 31329211.
Wingo TS, Cutler DJ, Yarab N, Kelly CM, Glass JD (2011). "The heritability of amyotrophic lateral sclerosis in a clinically ascertained United States research registry". PLOS ONE. 6 (11): e27985. Bibcode:2011PLoSO...627985W. doi:10.1371/journal.pone.0027985. PMC 3222666. PMID 22132186.
Goutman SA, Hardiman O, Al-Chalabi A, Chió A, Savelieff MG, Kiernan MC, et al. (May 2022). "Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis". The Lancet. Neurology. 21 (5): 465–479. doi:10.1016/S1474-4422(21)00414-2. PMC 9513754. PMID 35334234.
van Eenennaam RM, Koppenol LS, Kruithof WJ, Kruitwagen-van Reenen ET, Pieters S, van Es MA, et al. (November 2021). "Discussing Personalized Prognosis Empowers Patients with Amyotrophic Lateral Sclerosis to Regain Control over Their Future: A Qualitative Study". Brain Sciences. 11 (12): 1597. doi:10.3390/brainsci11121597. PMC 8699408. PMID 34942899.
Grad LI, Rouleau GA, Ravits J, Cashman NR (August 2017). "Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS)". Cold Spring Harbor Perspectives in Medicine. 7 (8): a024117. doi:10.1101/cshperspect.a024117. PMC 5538408. PMID 28003278.
Arora RD, Khan YS (2023). "Motor Neuron Disease". StatPearls. Treasure Island (FL): StatPearls Publishing. PMID 32809609. Retrieved 27 August 2023.
Jawdat O, Statland JM, Barohn RJ, Katz JS, Dimachkie MM (November 2015). "Amyotrophic Lateral Sclerosis Regional Variants (Brachial Amyotrophic Diplegia, Leg Amyotrophic Diplegia, and Isolated Bulbar Amyotrophic Lateral Sclerosis)". Neurologic Clinics. 33 (4): 775–785. doi:10.1016/j.ncl.2015.07.003. PMC 4629514. PMID 26515621.
Zhang H, Chen L, Tian J, Fan D (October 2021). "Disease duration of progression is helpful in identifying isolated bulbar palsy of amyotrophic lateral sclerosis". BMC Neurology. 21 (1): 405. doi:10.1186/s12883-021-02438-8. PMC 8532334. PMID 34686150.
Mehta PR, Jones AR, Opie-Martin S, Shatunov A, Iacoangeli A, Khleifat AA, et al. (1 March 2019). "Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias". Journal of Neurology, Neurosurgery & Psychiatry. 90 (3): 268–271. doi:10.1136/jnnp-2018-319089. ISSN 0022-3050. PMC 6518463. PMID 30270202.
Lehky T, Grunseich C (November 2021). "Juvenile Amyotrophic Lateral Sclerosis: A Review". Genes. 12 (12): 1935. doi:10.3390/genes12121935. PMC 8701111. PMID 34946884.
Teoh HL, Carey K, Sampaio H, Mowat D, Roscioli T, Farrar M (2017). "Inherited Paediatric Motor Neuron Disorders: Beyond Spinal Muscular Atrophy". Neural Plasticity. 2017: 6509493. doi:10.1155/2017/6509493. PMC 5467325. PMID 28634552.
Ravits J, Appel S, Baloh RH, Barohn R, Brooks BR, Elman L, et al. (May 2013). "Deciphering amyotrophic lateral sclerosis: what phenotype, neuropathology and genetics are telling us about pathogenesis". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 14 (Suppl 1): 5–18. doi:10.3109/21678421.2013.778548. PMC 3779649. PMID 23678876.
Gromicho M, Figueiral M, Uysal H, Grosskreutz J, Kuzma-Kozakiewicz M, Pinto S, et al. (July 2020). "Spreading in ALS: The relative impact of upper and lower motor neuron involvement". Annals of Clinical and Translational Neurology. 7 (7): 1181–1192. doi:10.1002/acn3.51098. PMC 7359118. PMID 32558369.
Wong C, Stavrou M, Elliott E, Gregory JM, Leigh N, Pinto AA, et al. (2021). "Clinical trials in amyotrophic lateral sclerosis: a systematic review and perspective". Brain Communications. 3 (4): fcab242. doi:10.1093/braincomms/fcab242. PMC 8659356. PMID 34901853.
Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. (November 2014). "The PRO-ACT database: design, initial analyses, and predictive features". Neurology. 83 (19): 1719–1725. doi:10.1212/WNL.0000000000000951. PMC 4239834. PMID 25298304.
Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, et al. (March 2016). "How common are ALS plateaus and reversals?". Neurology. 86 (9): 808–812. doi:10.1212/WNL.0000000000002251. PMC 4793781. PMID 26658909.
Yunusova Y, Plowman EK, Green JR, Barnett C, Bede P (2019). "Clinical Measures of Bulbar Dysfunction in ALS". Frontiers in Neurology. 10: 106. doi:10.3389/fneur.2019.00106. PMC 6389633. PMID 30837936.
Beukelman D, Fager S, Nordness A (2011). "Communication Support for People with ALS". Neurology Research International. 2011: 714693. doi:10.1155/2011/714693. PMC 3096454. PMID 21603029.
Kuzma-Kozakiewicz M, Andersen PM, Ciecwierska K, Vázquez C, Helczyk O, Loose M, et al. (September 2019). "An observational study on quality of life and preferences to sustain life in locked-in state". Neurology. 93 (10): e938 – e945. doi:10.1212/WNL.0000000000008064. PMC 6745736. PMID 31391247.
Fang T, Al Khleifat A, Stahl DR, Lazo La Torre C, Murphy C, Young C, et al. (May 2017). "Comparison of the King's and MiToS staging systems for ALS". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 18 (3–4): 227–232. doi:10.1080/21678421.2016.1265565. PMC 5425622. PMID 28054828.
Martin S, Al Khleifat A, Al-Chalabi A (2017). "What causes amyotrophic lateral sclerosis?". F1000Research. 6: 371. doi:10.12688/f1000research.10476.1. PMC 5373425. PMID 28408982.
Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, et al. (October 2018). "ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS". Neurology. 91 (15): e1370 – e1380. doi:10.1212/WNL.0000000000006317. PMC 6177274. PMID 30209236.
Renton AE, Chiò A, Traynor BJ (January 2014). "State of play in amyotrophic lateral sclerosis genetics". Nature Neuroscience. 17 (1): 17–23. doi:10.1038/nn.3584. hdl:2318/156177. PMC 4544832. PMID 24369373.
McNeill A, Amador MD, Bekker H, Clarke A, Crook A, Cummings C, et al. (June 2022). "Predictive genetic testing for Motor neuron disease: time for a guideline?". European Journal of Human Genetics. 30 (6): 635–636. doi:10.1038/s41431-022-01093-y. PMC 9177585. PMID 35379930.
Müller K, Oh KW, Nordin A, Panthi S, Kim SH, Nordin F, et al. (February 2022). "De novo mutations in SOD1 are a cause of ALS". Journal of Neurology, Neurosurgery, and Psychiatry. 93 (2): 201–206. doi:10.1136/jnnp-2021-327520. PMC 8784989. PMID 34518333.
Mehta PR, Iacoangeli A, Opie-Martin S, van Vugt JJ, Al Khleifat A, Bredin A, et al. (19 December 2022). "The impact of age on genetic testing decisions in amyotrophic lateral sclerosis". Brain. 145 (12): 4440–4447. doi:10.1093/brain/awac279. ISSN 0006-8950. PMC 9762932. PMID 36162820.
Salmon K, Kiernan MC, Kim SH, Andersen PM, Chio A, van den Berg LH, et al. (May 2022). "The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis". Brain. 145 (4): 1207–1210. doi:10.1093/brain/awab472. PMC 9129091. PMID 35020823. Archived from the original on 27 May 2023. Retrieved 27 May 2023.
Vitturi BK, Montecucco A, Rahmani A, Dini G, Durando P (15 November 2023). "Occupational risk factors for multiple sclerosis: a systematic review with meta-analysis". Frontiers in Public Health. 11 (2023): Introduction. Bibcode:2023FrPH...1185103V. doi:10.3389/fpubh.2023.1285103. PMC 10694508. PMID 38054069.
Parkin Kullmann JA, Hayes S, Pamphlett R (October 2018). "Are people with amyotrophic lateral sclerosis (ALS) particularly nice? An international online case-control study of the Big Five personality factors". Brain and Behavior. 8 (10): e01119. doi:10.1002/brb3.1119. PMC 6192405. PMID 30239176.
Mehl T, Jordan B, Zierz S (January 2017). ""Patients with amyotrophic lateral sclerosis (ALS) are usually nice persons"-How physicians experienced in ALS see the personality characteristics of their patients". Brain and Behavior. 7 (1): e00599. doi:10.1002/brb3.599. PMC 5256182. PMID 28127517.
White JA, Banerjee R, Gunawardena S (May 2016). "Axonal Transport and Neurodegeneration: How Marine Drugs Can Be Used for the Development of Therapeutics". Marine Drugs. 14 (5): 102. doi:10.3390/md14050102. PMC 4882576. PMID 27213408.
Ng Kee Kwong KC, Mehta AR, Nedergaard M, Chandran S (August 2020). "Defining novel functions for cerebrospinal fluid in ALS pathophysiology". Acta Neuropathologica Communications. 8 (1): 140. doi:10.1186/s40478-020-01018-0. PMC 7439665. PMID 32819425.
Van Damme P, Robberecht W, Van Den Bosch L (May 2017). "Modelling amyotrophic lateral sclerosis: progress and possibilities". Disease Models & Mechanisms. 10 (5): 537–549. doi:10.1242/dmm.029058. PMC 5451175. PMID 28468939.
Alsultan AA, Waller R, Heath PR, Kirby J (2016). "The genetics of amyotrophic lateral sclerosis: current insights". Degenerative Neurological and Neuromuscular Disease. 6: 49–64. doi:10.2147/DNND.S84956. PMC 6053097. PMID 30050368.
Shang Y, Huang EJ (September 2016). "Mechanisms of FUS mutations in familial amyotrophic lateral sclerosis". Brain Research. 1647: 65–78. doi:10.1016/j.brainres.2016.03.036. PMC 5003642. PMID 27033831.
Mehta PR, Brown AL, Ward ME, Fratta P (15 March 2023). "The era of cryptic exons: implications for ALS-FTD". Molecular Neurodegeneration. 18 (1): 16. doi:10.1186/s13024-023-00608-5. ISSN 1750-1326. PMC 10018954. PMID 36922834.
Gitler AD, Tsuiji H (September 2016). "There has been an awakening: Emerging mechanisms of C9orf72 mutations in FTD/ALS". Brain Research. 1647: 19–29. doi:10.1016/j.brainres.2016.04.004. PMC 5003651. PMID 27059391.
Mehta AR, Gregory JM, Dando O, Carter RN, Burr K, Nanda J, et al. (February 2021). "Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis". Acta Neuropathologica. 141 (2): 257–279. doi:10.1007/s00401-020-02252-5. PMC 7847443. PMID 33398403.
Verber NS, Shepheard SR, Sassani M, McDonough HE, Moore SA, Alix JJ, et al. (2019). "Biomarkers in Motor Neuron Disease: A State of the Art Review". Frontiers in Neurology. 10: 291. doi:10.3389/fneur.2019.00291. PMC 6456669. PMID 31001186.
Joyce NC, Carter GT (May 2013). "Electrodiagnosis in persons with amyotrophic lateral sclerosis". PM&R. 5 (5 Suppl): S89 – S95. doi:10.1016/j.pmrj.2013.03.020. PMC 4590769. PMID 23523708.
Radunovic A, Annane D, Rafiq MK, Brassington R, Mustfa N (October 2017). "Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease". The Cochrane Database of Systematic Reviews. 10 (10): CD004427. doi:10.1002/14651858.CD004427.pub4. PMC 6485636. PMID 28982219.
Sulistyo A, Abrahao A, Freitas ME, Ritsma B, Zinman L (August 2023). "Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease". The Cochrane Database of Systematic Reviews. 2023 (8): CD004030. doi:10.1002/14651858.CD004030.pub4. PMC 10413437. PMID 37579081.
Miller RG, Mitchell JD, Moore DH (March 2012). "Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)". The Cochrane Database of Systematic Reviews. 2012 (3): CD001447. doi:10.1002/14651858.CD001447.pub3. PMC 7055506. PMID 22419278.
Dorst J, Ludolph AC, Huebers A (2018). "Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis". Therapeutic Advances in Neurological Disorders. 11: 1756285617734734. doi:10.1177/1756285617734734. PMC 5784546. PMID 29399045.
Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. (June 2015). "Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis". Neurology. 84 (22): 2247–2257. doi:10.1212/WNL.0000000000001642. PMC 4456658. PMID 25934855.
Liu X, Shang H, Wei Q, Yao X, Lian L, Dang J, et al. (24 February 2025). "Tetramethylpyrazine Nitrone in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial". JAMA Network Open. 8 (2): e2461055. doi:10.1001/jamanetworkopen.2024.61055. ISSN 2574-3805. PMC 11851239. PMID 39992655.
Paganoni S, Karam C, Joyce N, Bedlack R, Carter GT (2015). "Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis". NeuroRehabilitation. 37 (1): 53–68. doi:10.3233/NRE-151240. PMC 5223769. PMID 26409693.
Majmudar S, Wu J, Paganoni S (July 2014). "Rehabilitation in amyotrophic lateral sclerosis: why it matters". Muscle & Nerve. 50 (1): 4–13. doi:10.1002/mus.24202. PMC 4433000. PMID 24510737.
Chiò A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. (2013). "Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature". Neuroepidemiology. 41 (2): 118–130. doi:10.1159/000351153. PMC 4049265. PMID 23860588.
Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. (November 2018). "Prevalence of Amyotrophic Lateral Sclerosis – United States, 2015". MMWR. Morbidity and Mortality Weekly Report. 67 (46): 1285–1289. doi:10.15585/mmwr.mm6746a1. PMC 5858037. PMID 30462626.
Arthur KC, Calvo A, Price TR, Geiger JT, Chiò A, Traynor BJ (August 2016). "Projected increase in amyotrophic lateral sclerosis from 2015 to 2040". Nature Communications. 7 (12408): 12408. Bibcode:2016NatCo...712408A. doi:10.1038/ncomms12408. PMC 4987527. PMID 27510634.
Wijesekera LC, Mathers S, Talman P, Galtrey C, Parkinson MH, Ganesalingam J, et al. (March 2009). "Natural history and clinical features of the flail arm and flail leg ALS variants". Neurology. 72 (12): 1087–1094. doi:10.1212/01.wnl.0000345041.83406.a2. PMC 2821838. PMID 19307543.
Gordon PH (October 2013). "Amyotrophic Lateral Sclerosis: An update for 2013 Clinical Features, Pathophysiology, Management and Therapeutic Trials". Aging and Disease. 4 (5): 295–310. doi:10.14336/AD.2013.0400295. PMC 3794725. PMID 24124634.

ninds.nih.gov

"Amyotrophic Lateral Sclerosis (ALS) Fact Sheet". National Institute of Neurological Disorders and Stroke. Archived from the original on 5 January 2017. Retrieved 22 October 2020.
"Motor Neuron Diseases Fact Sheet". www.ninds.nih.gov. National Institute of Neurological Disorders and Stroke. Archived from the original on 10 October 2020. Retrieved 27 October 2020.

oup.com

academic.oup.com

Mehta PR, Iacoangeli A, Opie-Martin S, van Vugt JJ, Al Khleifat A, Bredin A, et al. (19 December 2022). "The impact of age on genetic testing decisions in amyotrophic lateral sclerosis". Brain. 145 (12): 4440–4447. doi:10.1093/brain/awac279. ISSN 0006-8950. PMC 9762932. PMID 36162820.
Salmon K, Kiernan MC, Kim SH, Andersen PM, Chio A, van den Berg LH, et al. (May 2022). "The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis". Brain. 145 (4): 1207–1210. doi:10.1093/brain/awab472. PMC 9129091. PMID 35020823. Archived from the original on 27 May 2023. Retrieved 27 May 2023.

qut.edu.au

eprints.qut.edu.au

He J, Mangelsdorf M, Fan D, Bartlett P, Brown MA (December 2015). "Amyotrophic Lateral Sclerosis Genetic Studies: From Genome-wide Association Mapping to Genome Sequencing" (PDF). The Neuroscientist. 21 (6): 599–615. doi:10.1177/1073858414555404. PMID 25378359. S2CID 3437565. Archived (PDF) from the original on 7 May 2020. Retrieved 20 December 2019.

semanticscholar.org

api.semanticscholar.org

Kwan J, Vullaganti M (September 2022). "Amyotrophic lateral sclerosis mimics". Muscle & Nerve. 66 (3): 240–252. doi:10.1002/mus.27567. PMID 35607838. S2CID 249014375.
Hobson EV, McDermott CJ (September 2016). "Supportive and symptomatic management of amyotrophic lateral sclerosis" (PDF). Nature Reviews. Neurology. 12 (9): 526–538. doi:10.1038/nrneurol.2016.111. PMID 27514291. S2CID 8547381. Archived (PDF) from the original on 1 December 2020. Retrieved 20 December 2019.
van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. (November 2017). "Amyotrophic lateral sclerosis". Lancet. 390 (10107): 2084–2098. doi:10.1016/S0140-6736(17)31287-4. hdl:2318/1673185. PMID 28552366. S2CID 24483077.
Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. (October 2017). "Amyotrophic lateral sclerosis" (PDF). Nature Reviews. Disease Primers. 3 (17071): 17071. doi:10.1038/nrdp.2017.71. PMID 28980624. S2CID 1002680. Archived (PDF) from the original on 1 December 2020. Retrieved 20 December 2019.
Connolly S, Galvin M, Hardiman O (April 2015). "End-of-life management in patients with amyotrophic lateral sclerosis". The Lancet. Neurology. 14 (4): 435–442. doi:10.1016/S1474-4422(14)70221-2. PMID 25728958. S2CID 34109901.
Pupillo E, Messina P, Logroscino G, Beghi E (February 2014). "Long-term survival in amyotrophic lateral sclerosis: a population-based study". Annals of Neurology. 75 (2): 287–297. doi:10.1002/ana.24096. PMID 24382602. S2CID 205345019.
Gautier G, Verschueren A, Monnier A, Attarian S, Salort-Campana E, Pouget J (August 2010). "ALS with respiratory onset: clinical features and effects of non-invasive ventilation on the prognosis". Amyotrophic Lateral Sclerosis. 11 (4): 379–382. doi:10.3109/17482960903426543. PMID 20001486. S2CID 27672209.
Swinnen B, Robberecht W (November 2014). "The phenotypic variability of amyotrophic lateral sclerosis". Nature Reviews. Neurology. 10 (11): 661–670. doi:10.1038/nrneurol.2014.184. PMID 25311585. S2CID 205516010. Archived from the original on 31 December 2018. Retrieved 22 August 2018.
Al-Chalabi A, Hardiman O, Kiernan MC, Chiò A, Rix-Brooks B, van den Berg LH (October 2016). "Amyotrophic lateral sclerosis: moving towards a new classification system". The Lancet. Neurology. 15 (11): 1182–1194. doi:10.1016/S1474-4422(16)30199-5. hdl:2318/1636249. PMID 27647646. S2CID 45285510.
Chiò A, Mora G, Lauria G (February 2017). "Pain in amyotrophic lateral sclerosis". The Lancet. Neurology. 16 (2): 144–157. arXiv:1607.02870. doi:10.1016/S1474-4422(16)30358-1. PMID 27964824. S2CID 38905437.
Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. (October 1999). "The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)". Journal of the Neurological Sciences. 169 (1–2): 13–21. doi:10.1016/s0022-510x(99)00210-5. PMID 10540002. S2CID 7057926.
Creemers H, Grupstra H, Nollet F, van den Berg LH, Beelen A (June 2015). "Prognostic factors for the course of functional status of patients with ALS: a systematic review". Journal of Neurology. 262 (6): 1407–1423. doi:10.1007/s00415-014-7564-8. PMID 25385051. S2CID 31734765.
Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME (2010). "Clinical significance in the change of decline in ALSFRS-R". Amyotrophic Lateral Sclerosis (Journal Article). 11 (1–2): 178–180. doi:10.3109/17482960903093710. PMID 19634063. S2CID 207619689.
Lui AJ, Byl NN (June 2009). "A systematic review of the effect of moderate intensity exercise on function and disease progression in amyotrophic lateral sclerosis". Journal of Neurologic Physical Therapy. 33 (2): 68–87. doi:10.1097/NPT.0b013e31819912d0. PMID 19556916. S2CID 7650356.
O'Brien D, Stavroulakis T, Baxter S, Norman P, Bianchi S, Elliott M, et al. (September 2019). "The optimisation of noninvasive ventilation in amyotrophic lateral sclerosis: a systematic review". The European Respiratory Journal. 54 (3): 1900261. doi:10.1183/13993003.00261-2019. PMID 31273038. S2CID 195805546.
Bede P, Oliver D, Stodart J, van den Berg L, Simmons Z, O Brannagáin D, et al. (April 2011). "Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives". Journal of Neurology, Neurosurgery, and Psychiatry. 82 (4): 413–418. doi:10.1136/jnnp.2010.232637. hdl:2262/59035. PMID 21297150. S2CID 7043837. Archived from the original on 28 May 2023. Retrieved 30 April 2023.
Corcia P, Pradat PF, Salachas F, Bruneteau G, Forestier N, Seilhean D, et al. (1 January 2008). "Causes of death in a post-mortem series of ALS patients". Amyotrophic Lateral Sclerosis. 9 (1): 59–62. doi:10.1080/17482960701656940. PMID 17924236. S2CID 40367873.
Chiò A, Calvo A, Moglia C, Mazzini L, Mora G (July 2011). "Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study" (PDF). Journal of Neurology, Neurosurgery, and Psychiatry. 82 (7): 740–746. doi:10.1136/jnnp.2010.235952. PMID 21402743. S2CID 13416164. Archived (PDF) from the original on 24 November 2022. Retrieved 4 August 2022.
Yang T, Hou Y, Li C, Cao B, Cheng Y, Wei Q, et al. (July 2021). "Risk factors for cognitive impairment in amyotrophic lateral sclerosis: a systematic review and meta-analysis". Journal of Neurology, Neurosurgery, and Psychiatry. 92 (7): 688–693. doi:10.1136/jnnp-2020-325701. PMID 33563800. S2CID 231858696.
Wicks P (July 2007). "Excessive yawning is common in the bulbar-onset form of ALS". Acta Psychiatrica Scandinavica. 116 (1): 76, author reply 76–76, author reply 77. doi:10.1111/j.1600-0447.2007.01025.x. PMID 17559605. S2CID 12807996.
Sauvé WM (December 2016). "Recognizing and treating pseudobulbar affect". CNS Spectrums. 21 (S1): 34–44. doi:10.1017/S1092852916000791. PMID 28044945. S2CID 21066800.
Raaphorst J, Beeldman E, De Visser M, De Haan RJ, Schmand B (October 2012). "A systematic review of behavioural changes in motor neuron disease". Amyotrophic Lateral Sclerosis. 13 (6): 493–501. doi:10.3109/17482968.2012.656652. PMID 22424127. S2CID 22224140.
Beeldman E, Raaphorst J, Klein Twennaar M, de Visser M, Schmand BA, de Haan RJ (June 2016). "The cognitive profile of ALS: a systematic review and meta-analysis update". Journal of Neurology, Neurosurgery, and Psychiatry. 87 (6): 611–619. doi:10.1136/jnnp-2015-310734. PMID 26283685. S2CID 22082109.
Al-Chalabi A, Hardiman O (November 2013). "The epidemiology of ALS: a conspiracy of genes, environment and time". Nature Reviews. Neurology. 9 (11): 617–628. doi:10.1038/nrneurol.2013.203. PMID 24126629. S2CID 25040863.
He J, Mangelsdorf M, Fan D, Bartlett P, Brown MA (December 2015). "Amyotrophic Lateral Sclerosis Genetic Studies: From Genome-wide Association Mapping to Genome Sequencing" (PDF). The Neuroscientist. 21 (6): 599–615. doi:10.1177/1073858414555404. PMID 25378359. S2CID 3437565. Archived (PDF) from the original on 7 May 2020. Retrieved 20 December 2019.
De Oliveira HM, Soma A, Baker MR, Turner MR, Talbot K, Williams TL (August 2023). "A survey of current practice in genetic testing in amyotrophic lateral sclerosis in the UK and Republic of Ireland: implications for future planning". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 24 (5–6): 405–413. doi:10.1080/21678421.2022.2150556. PMID 36458618. S2CID 254150195.
Wang MD, Little J, Gomes J, Cashman NR, Krewski D (July 2017). "Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis". Neurotoxicology. 61: 101–130. Bibcode:2017NeuTx..61..101W. doi:10.1016/j.neuro.2016.06.015. PMID 27377857. S2CID 33604904. Archived from the original on 17 November 2022. Retrieved 27 May 2023.
Grossman AB, Levin BE, Bradley WG (March 2006). "Premorbid personality characteristics of patients with ALS". Amyotrophic Lateral Sclerosis. 7 (1): 27–31. doi:10.1080/14660820510012004. PMID 16546756. S2CID 20998807.
Robberecht W, Philips T (April 2013). "The changing scene of amyotrophic lateral sclerosis". Nature Reviews. Neuroscience. 14 (4): 248–264. doi:10.1038/nrn3430. PMID 23463272. S2CID 208941.
Brown RH, Al-Chalabi A (July 2017). "Amyotrophic Lateral Sclerosis". The New England Journal of Medicine. 377 (2): 162–172. doi:10.1056/NEJMra1603471. PMID 28700839. S2CID 205117619. Archived from the original on 25 February 2021. Retrieved 20 December 2019.
Okamoto K, Mizuno Y, Fujita Y (April 2008). "Bunina bodies in amyotrophic lateral sclerosis". Neuropathology. 28 (2): 109–115. doi:10.1111/j.1440-1789.2007.00873.x. PMID 18069968. S2CID 34398467.
Eisen A, Krieger C (November 2013). "Ethical considerations in the management of amyotrophic lateral sclerosis". Progress in Neurobiology. 110: 45–53. doi:10.1016/j.pneurobio.2013.05.001. PMID 23735671. S2CID 26282198.
Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. (March 2012). "EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force". European Journal of Neurology. 19 (3): 360–375. doi:10.1111/j.1468-1331.2011.03501.x. PMID 21914052. S2CID 5746940.
Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. (September 2022). "Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS". The New England Journal of Medicine. 387 (12): 1099–1110. doi:10.1056/NEJMoa2204705. PMID 36129998. S2CID 252438252.
Macpherson CE, Bassile CC (July 2016). "Pulmonary Physical Therapy Techniques to Enhance Survival in Amyotrophic Lateral Sclerosis: A Systematic Review". Journal of Neurologic Physical Therapy. 40 (3): 165–175. doi:10.1097/NPT.0000000000000136. PMID 27164308. S2CID 7279853.
Spataro R, Lo Re M, Piccoli T, Piccoli F, La Bella V (September 2010). "Causes and place of death in Italian patients with amyotrophic lateral sclerosis". Acta Neurologica Scandinavica. 122 (3): 217–223. doi:10.1111/j.1600-0404.2009.01290.x. PMID 20078446. S2CID 26479278.
Hardiman O, Al-Chalabi A, Brayne C, Beghi E, van den Berg LH, Chio A, et al. (July 2017). "The changing picture of amyotrophic lateral sclerosis: lessons from European registers". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (7): 557–563. doi:10.1136/jnnp-2016-314495. hdl:2318/1633611. PMID 28285264. S2CID 52871105. Archived from the original on 21 December 2019. Retrieved 22 August 2018.
Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP (July 2017). "Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (7): 540–549. doi:10.1136/jnnp-2016-315018. PMID 28057713. S2CID 41974606.
Visser J, de Jong JM, de Visser M (February 2008). "The history of progressive muscular atrophy: syndrome or disease?". Neurology. 70 (9): 723–727. doi:10.1212/01.wnl.0000302187.20239.93. PMID 18299524. S2CID 22629725.
Wilbourn AJ (October 1998). "Clinical neurophysiology in the diagnosis of amyotrophic lateral sclerosis: the Lambert and the El Escorial criteria". Journal of the Neurological Sciences. 160 (Supplement 1): S25 – S29. doi:10.1016/s0022-510x(98)00194-4. PMID 9851644. S2CID 32884687.
Brooks BR (July 1994). "El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors". Journal of the Neurological Sciences. 124 (Supplement): 96–107. doi:10.1016/0022-510x(94)90191-0. PMID 7807156. S2CID 32678612.
Brooks BR, Miller RG, Swash M, Munsat TL (December 2000). "El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis". Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 1 (5): 293–299. doi:10.1080/146608200300079536. PMID 11464847. S2CID 22725949.
de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J, et al. (March 2008). "Electrodiagnostic criteria for diagnosis of ALS". Clinical Neurophysiology. 119 (3): 497–503. doi:10.1016/j.clinph.2007.09.143. PMID 18164242. S2CID 14851649.
Shefner JM, Al-Chalabi A, Baker MR, Cui LY, de Carvalho M, Eisen A, et al. (August 2020). "A proposal for new diagnostic criteria for ALS". Clinical Neurophysiology. 131 (8): 1975–1978. doi:10.1016/j.clinph.2020.04.005. hdl:10451/48432. PMID 32387049. S2CID 215823371.
Goetz CG (March 2000). "Amyotrophic lateral sclerosis: early contributions of Jean-Martin Charcot". Muscle & Nerve. 23 (3): 336–343. doi:10.1002/(SICI)1097-4598(200003)23:3<336::AID-MUS4>3.0.CO;2-L. PMID 10679709. S2CID 5917354.
Huynh W, Simon NG, Grosskreutz J, Turner MR, Vucic S, Kiernan MC (July 2016). "Assessment of the upper motor neuron in amyotrophic lateral sclerosis". Clinical Neurophysiology. 127 (7): 2643–2660. doi:10.1016/j.clinph.2016.04.025. PMID 27291884. S2CID 3757685.
Wicks P (December 2014). "The ALS ice bucket challenge – can a splash of water reinvigorate a field?". Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 15 (7–8): 479–480. doi:10.3109/21678421.2014.984725. PMID 25431828. S2CID 207581186.

uni-muenchen.de

epub.ub.uni-muenchen.de

Bede P, Oliver D, Stodart J, van den Berg L, Simmons Z, O Brannagáin D, et al. (April 2011). "Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives". Journal of Neurology, Neurosurgery, and Psychiatry. 82 (4): 413–418. doi:10.1136/jnnp.2010.232637. hdl:2262/59035. PMID 21297150. S2CID 7043837. Archived from the original on 28 May 2023. Retrieved 30 April 2023.

web.archive.org

"Amyotrophic Lateral Sclerosis (ALS) Fact Sheet". National Institute of Neurological Disorders and Stroke. Archived from the original on 5 January 2017. Retrieved 22 October 2020.
Hobson EV, McDermott CJ (September 2016). "Supportive and symptomatic management of amyotrophic lateral sclerosis" (PDF). Nature Reviews. Neurology. 12 (9): 526–538. doi:10.1038/nrneurol.2016.111. PMID 27514291. S2CID 8547381. Archived (PDF) from the original on 1 December 2020. Retrieved 20 December 2019.
"Motor Neuron Diseases Fact Sheet". www.ninds.nih.gov. National Institute of Neurological Disorders and Stroke. Archived from the original on 10 October 2020. Retrieved 27 October 2020.
Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. (October 2017). "Amyotrophic lateral sclerosis" (PDF). Nature Reviews. Disease Primers. 3 (17071): 17071. doi:10.1038/nrdp.2017.71. PMID 28980624. S2CID 1002680. Archived (PDF) from the original on 1 December 2020. Retrieved 20 December 2019.
"Understanding ALS". The ALS Association. Archived from the original on 26 October 2020. Retrieved 28 October 2020.
"FDA-Approved Drugs for Treating ALS". The ALS Association. Archived from the original on 25 April 2023. Retrieved 25 April 2023.
Swinnen B, Robberecht W (November 2014). "The phenotypic variability of amyotrophic lateral sclerosis". Nature Reviews. Neurology. 10 (11): 661–670. doi:10.1038/nrneurol.2014.184. PMID 25311585. S2CID 205516010. Archived from the original on 31 December 2018. Retrieved 22 August 2018.
"Motor neurone disease". UK: National Health Service. 15 January 2018. Archived from the original on 29 December 2014. Retrieved 24 October 2020.
Bede P, Oliver D, Stodart J, van den Berg L, Simmons Z, O Brannagáin D, et al. (April 2011). "Palliative care in amyotrophic lateral sclerosis: a review of current international guidelines and initiatives". Journal of Neurology, Neurosurgery, and Psychiatry. 82 (4): 413–418. doi:10.1136/jnnp.2010.232637. hdl:2262/59035. PMID 21297150. S2CID 7043837. Archived from the original on 28 May 2023. Retrieved 30 April 2023.
Chiò A, Calvo A, Moglia C, Mazzini L, Mora G (July 2011). "Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study" (PDF). Journal of Neurology, Neurosurgery, and Psychiatry. 82 (7): 740–746. doi:10.1136/jnnp.2010.235952. PMID 21402743. S2CID 13416164. Archived (PDF) from the original on 24 November 2022. Retrieved 4 August 2022.
Landau E (20 September 2009). "Stephen Hawking serves as role model for ALS patients". CNN. Archived from the original on 15 August 2016.
"Amyotrophic lateral sclerosis (ALS) - Symptoms and causes". Mayo Clinic. Archived from the original on 6 April 2022. Retrieved 6 April 2022.
"Who Gets ALS?". The ALS Association. Archived from the original on 6 April 2022. Retrieved 6 April 2022.
He J, Mangelsdorf M, Fan D, Bartlett P, Brown MA (December 2015). "Amyotrophic Lateral Sclerosis Genetic Studies: From Genome-wide Association Mapping to Genome Sequencing" (PDF). The Neuroscientist. 21 (6): 599–615. doi:10.1177/1073858414555404. PMID 25378359. S2CID 3437565. Archived (PDF) from the original on 7 May 2020. Retrieved 20 December 2019.
Salmon K, Kiernan MC, Kim SH, Andersen PM, Chio A, van den Berg LH, et al. (May 2022). "The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis". Brain. 145 (4): 1207–1210. doi:10.1093/brain/awab472. PMC 9129091. PMID 35020823. Archived from the original on 27 May 2023. Retrieved 27 May 2023.
Wang MD, Little J, Gomes J, Cashman NR, Krewski D (July 2017). "Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis". Neurotoxicology. 61: 101–130. Bibcode:2017NeuTx..61..101W. doi:10.1016/j.neuro.2016.06.015. PMID 27377857. S2CID 33604904. Archived from the original on 17 November 2022. Retrieved 27 May 2023.
Brown RH, Al-Chalabi A (July 2017). "Amyotrophic Lateral Sclerosis". The New England Journal of Medicine. 377 (2): 162–172. doi:10.1056/NEJMra1603471. PMID 28700839. S2CID 205117619. Archived from the original on 25 February 2021. Retrieved 20 December 2019.
Stickler DE. Lorenzo N (ed.). "Lambert-Eaton Myasthenic Syndrome (LEMS)". Misc.medscape.com. Archived from the original on 14 May 2013. Retrieved 18 April 2013.
"Lambert-Eaton Myasthenic Syndrome: About". LEMS.com. BioMarin Pharmaceutical Inc. Archived from the original on 20 January 2013. Retrieved 18 April 2013.
"Amyotrophic Lateral Sclerosis (ALS)". American Speech-Language-Hearing Association, Rockville, MD. Archived from the original on 2 August 2012. Retrieved 30 November 2016.
Center for Drug Evaluation and Research (16 June 2022). "FDA Approves Oral Form for the treatment of adults with amyotrophic lateral sclerosis (ALS)". U.S. Food and Drug Administration. Archived from the original on 12 May 2022. Retrieved 25 April 2023.
"AMX0035 (RELYVRIO)". The ALS Association. Archived from the original on 25 April 2023. Retrieved 25 April 2023.
"FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene" (Press release). U.S. Food and Drug Administration (FDA). 25 April 2023. Archived from the original on 25 April 2023. Retrieved 25 April 2023.
Hardiman O, Al-Chalabi A, Brayne C, Beghi E, van den Berg LH, Chio A, et al. (July 2017). "The changing picture of amyotrophic lateral sclerosis: lessons from European registers". Journal of Neurology, Neurosurgery, and Psychiatry. 88 (7): 557–563. doi:10.1136/jnnp-2016-314495. hdl:2318/1633611. PMID 28285264. S2CID 52871105. Archived from the original on 21 December 2019. Retrieved 22 August 2018.
"What is ALS?". The ALS Association. Archived from the original on 21 December 2018. Retrieved 23 December 2018.
"ALS: Amyotrophic Lateral Sclerosis". Muscular Dystrophy Association. 18 December 2015. Archived from the original on 6 August 2018. Retrieved 23 December 2018.
Alexander E (20 August 2014). "George Bush delivers possibly the best ALS ice bucket challenge yet". The Independent. Archived from the original on 21 August 2014. Retrieved 20 August 2014.

whiterose.ac.uk

eprints.whiterose.ac.uk

Hobson EV, McDermott CJ (September 2016). "Supportive and symptomatic management of amyotrophic lateral sclerosis" (PDF). Nature Reviews. Neurology. 12 (9): 526–538. doi:10.1038/nrneurol.2016.111. PMID 27514291. S2CID 8547381. Archived (PDF) from the original on 1 December 2020. Retrieved 20 December 2019.
Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. (October 2017). "Amyotrophic lateral sclerosis" (PDF). Nature Reviews. Disease Primers. 3 (17071): 17071. doi:10.1038/nrdp.2017.71. PMID 28980624. S2CID 1002680. Archived (PDF) from the original on 1 December 2020. Retrieved 20 December 2019.

who.int

icd.who.int

"8B60 Motor neuron disease". ICD-11 for Mortality and Morbidity Statistics. World Health Organization. Archived from the original on 1 August 2018. Retrieved 24 January 2019.

worldcat.org

search.worldcat.org

Mehta PR, Jones AR, Opie-Martin S, Shatunov A, Iacoangeli A, Khleifat AA, et al. (1 March 2019). "Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias". Journal of Neurology, Neurosurgery & Psychiatry. 90 (3): 268–271. doi:10.1136/jnnp-2018-319089. ISSN 0022-3050. PMC 6518463. PMID 30270202.
Mehta PR, Iacoangeli A, Opie-Martin S, van Vugt JJ, Al Khleifat A, Bredin A, et al. (19 December 2022). "The impact of age on genetic testing decisions in amyotrophic lateral sclerosis". Brain. 145 (12): 4440–4447. doi:10.1093/brain/awac279. ISSN 0006-8950. PMC 9762932. PMID 36162820.
Frost B, Dubnau J (8 August 2024). "The Role of Retrotransposons and Endogenous Retroviruses in Age-Dependent Neurodegenerative Disorders". Annual Review of Neuroscience. 47 (1): 123–143. doi:10.1146/annurev-neuro-082823-020615. ISSN 0147-006X.
Mehta PR, Brown AL, Ward ME, Fratta P (15 March 2023). "The era of cryptic exons: implications for ALS-FTD". Molecular Neurodegeneration. 18 (1): 16. doi:10.1186/s13024-023-00608-5. ISSN 1750-1326. PMC 10018954. PMID 36922834.
Liu X, Shang H, Wei Q, Yao X, Lian L, Dang J, et al. (24 February 2025). "Tetramethylpyrazine Nitrone in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial". JAMA Network Open. 8 (2): e2461055. doi:10.1001/jamanetworkopen.2024.61055. ISSN 2574-3805. PMC 11851239. PMID 39992655.